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Abstract  1 
Abstract 
Dipeptidyl peptidase 4 (DP4/CD26) is a multifunctional serine exopeptidase. As dipeptidyl 
peptidase, DP4 modulates the functions of its substrates by specific truncation especially of 
Xaa-Pro dipeptides from the N-terminus. Neuropeptide Y (NPY) is of special interest as it 
represents one of the best substrates for DP4, and as it is involved in various physiological, 
psychological, and immune functions. Here, the NPY-DP4-axis was studied on three different 
levels: (1) cleavage of NPY by DP4/DP4-like peptidases, (2) its role in a newly developed 
congenic animal model of DP4 deficiency, and (3) within central processing of pain 
perception. 
Firstly, enzyme activity studies on DP4-like peptidases, with respect to their potential to 
truncate NPY, revealed that peripheral NPY is mainly truncated by serum and endothelial DP4 
whereas the intracellular dipeptidyl peptidase 8 and 9 possibly cleave NPY within the central 
nervous system (CNS). Initial co-transfection studies of DP4 and NPY in Cos-1 cells provided 
however no evidence for a vesicular co-localization of the peptidase and its substrate – thereby 
“opposing” the possibility of an intracellular cleavage of NPY by DP4.  
Secondly, in-depth characterization of congenic DP4 deficient DA rats revealed a number of 
beneficial metabolic effects including improved glucose tolerance – associated with increased 
levels of glucagons-like peptide 1 – and reduced diet-induced body weight gain. Furthermore, 
DP4 deficient rats exhibited diminished anxiety and stress-like responses in behavioural and 
endocrinal tests, probably due to a reduced N-terminal truncation of NPY (see third approach). 
In contrast to these “beneficial” effects, however, several immune alterations, e.g. differential 
leukocyte subset composition at baseline, blunted NK-cell and T-cell functions, were observed. 
These considerable consequences of DP4 deficiency point to potential adverse effects and 
question the concept of chronic use of DP4 inhibitors in a clinical setting, such as treatment of 
diabetes type II. Thirdly, the DP4-NPY axis was investigated with regard to its potential role in 
stress-induced analgesia. We showed that, depending on the contextual stress (habituated vs 
non-habitiuated), DP4 deficiency ameliorates stress-induced analgesia, thereby providing 
direct evidence for its stress-protective action within the CNS. 
In conclusion these studies illustrate that DP4 functions are highly important in various 
processes and that it will be hard to separate one aspect as a therapeutic target without taking 
others into account. Due to multiple actions of further DP4-like peptidases at various levels 
and sites, the upcoming DP4 inhibitors will have to act short-term, highly target- and site-
specific in order to minimize the risk of unwanted side effects. 
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Kurzzusammenfassung 
Die Serin-Exopeptidase Dipeptidyl Peptidase 4 (DP4/CD26) ist in zahlreichen biologischen 
Prozessen durch spezifische N-terminale Trunkierung von Substraten, speziell von Xaa-Pro 
Dipeptiden, involviert. Neuropeptid Y (NPY) ist als eines der besten Substrate von DP4 
aufgrund seiner umfangreichen Funktionen von besonderem Interesse. Die NPY-DP4-Achse 
wurde hier hinsichtlich dreier Aspekte untersucht: (1) Spaltung durch DP4-ähnliche 
Peptidasen, (2) Rolle im kongenen DP4-defizienten Tiermodell und (3) Rolle während der 
zentralen Verarbeitung von Schmerz. 
Zunächst zeigten Enzymaktivitätsstudien mit DP4-ähnlichen Peptidasen in Bezug auf deren 
Potential, NPY zu trunkieren, dass peripheres NPY hauptsächlich durch Serum- und 
endotheliale DP4 gespalten wird, während die intrazellulären Dipeptidyl Peptidasen 8 und 9 
von größerer Bedeutung bei der NPY-Spaltung im zentralen Nervensystem (ZNS) sind. Es 
ergaben sich jedoch in Kotransfektionsstudien keine Hinweise für eine intrazelluläre Spaltung 
von NPY durch DP4. Im zweiten Ansatz zeigte der DP4-defiziente kongene DA Ratten-
Substamm DA.F344-Dpp4m/SvH verbesserte metabolische Effekte, unter anderem verbesserte 
Glukosetoleranz im Zusammenhang mit erhöhten Spiegeln an Glucagon-ähnliches Peptid 1, 
sowie eine reduzierte diätinduzierte Gewichtszunahme. Interessanterweise zeigten 
Verhaltenstests und endokrine Untersuchungen reduzierte Angst und stressprotektive Effekte, 
die vermutlich durch die reduzierte N-terminale NPY-Trunkierung in DP4-defizienten Ratten 
verursacht wurden. Neben diesen scheinbar positiven Effekten der DP4-Defizienz wurden 
jedoch auch verschiedene Alterationen im Immunsystem, wie z.B. ein verändertes 
Leukozytenblutbild und eingeschränkte NK- und T-Zell-Funktionen festgestellt. Mit diesen 
Beobachtungen verweisen wir auf Nebeneffekte, welche wiederum das Konzept des 
chronischen Einsatzes von DP4-Inhibitoren in der Klinik in Frage stellen. In einem dritten 
Ansatz wurde die DP4-NPY-Achse im Hinblick auf ihre Rolle bei stressinduzierter Analgesie 
untersucht. Dabei konnten wir zeigen, dass DP4-Defizienz in Abhängigkeit vom Test-Stress-
Niveau (habituiert vs. non-habituiert), eine stressprotektive Wirkung im ZNS aufweist. 
Zusammenfassend zeigen die drei Publikationen, dass DP4 an einer Vielzahl wichtiger 
Prozesse beteiligt ist. Die Phänotypisierungsergebnisse der DA.F344-Dpp4m/SvH-Ratten 
machen deutlich, dass einzelne Aspekte der DP4 nicht isoliert betrachtet werden sollten, 
verweisen jedoch auch gleichzeitig auf neue therapeutische Ansatzpunkte wie z.B. Angst, 
Ernährung und Schmerz. Aufgrund der multiplen Aktionen weiterer DP4-ähnlicher Peptidasen 
müssen DP4-Inhibitoren höchst spezifisch und reversibel wirken, um das Risiko von 
ungewollten Nebenwirkungen zu minimieren. 
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1. Introduction 
Dipeptidyl peptidase 4 (DP4, EC 3.4.14.5) is a multifunctional serine exopeptidase that is also 
known as leukocyte differentiation marker CD26 [1, 2]. DP4 has been referred to in the 
literature by a wide variety of abbreviations including DPP IV, DP-IV, and DPP4. We chose 
the abbreviation DP4 in analogy to the more recently cloned dipeptidyl peptidases 8 and 9, 
which were abbreviated by DP8 and DP9. The membrane-bound form of DP4 is a type II 
transmembrane glycoprotein [3]. Due to the secondary structure of its catalytic domain, DP4 is 
classified as alpha/beta-hydrolase fold enzyme. According to its sequence homology around 
the seryl residue in the active site, the arrangement of the catalytic triad and the homologic 
structure in the C-terminus, DP4 is classified together amongst others with prolyl 
oligopeptidase (POP, EC 3.4.21.26) and acylaminoacyl peptidase (EC 3.4.19.1) into the family 
of prolyl oligopeptidases (S9) [4]. DP4 was discovered in rat liver homogenates by Hopsu-
Havu and Glenner in 1966 [5]. 
1.1. Structure and structural properties of DP4 
The cDNA of rat DP4 codes for a sequence of 767 amino acids (aa) that can be divided into 
five structural regions (Fig. 1). The highly conserved N-terminal cytosolic region, composed of 
six aa, is followed by a hydrophobic region of 22 aa – the transmembrane domain – which 
serves as signal peptide and membrane anchor [3]. The extracellular part of DP4 consists of 
739 aa and can further be divided into three regions. These are the glycosylated region, 
containing five of eight potential N-glycosylation sites of the extracellular region [6, 7], the 
cysteine-rich region, expressing ten of twelve cysteine residues [8], and the C-terminal 
catalytic region. The C-terminus harbors the active site of this enzyme, which comprises a triad 
of the catalytically active amino acids Ser631, Asp709 and His741 [9, 10]. The active Ser631 
of DP4 is situated in a so called ”nucleophile elbow“ in the sequence Gly-Trp-Ser-Tyr-Gly 
which is in agreement with the conserved sequence Gly-X-Ser-X-Gly for the / hydrolase 
family. 
There is a homology of 84,5% between human and rat DP4 cDNA [11]. Human DP4 is a 766 
aa sized molecule, has an additional N-glycosylation site on N281 (according to human 
numbering) [12] and the amino acids of the catalytic triad are in positions 630, 708 and 740. In 
contrast to rat DP4, human DP4 is able to bind adenosine deaminase (ADA) [12, 13]. 
Oligosaccharide side chains are reported to modulate biophysical and biological properties of 
glycoproteins such as protein folding, stability, translocation and cell adhesion processes. 
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However, the precise role of the glycosylations of DP4 is unknown. Fan et al. [14] 
demonstrated that N-glycans are essential for folding and biological stability of this molecule. 
O-glycosylation has been controversially discussed. Whereas no O-glycosylation could be 
detected in membrane-bound DP4 from rat liver [15-17], Naim et al. and Matter et al. reported 
on O-glycosylation of DP4 on human intestinal brush-border cells and Caco-2 cells (human 
adenocarcinoma cells of colorectal origin), suggesting that O-glycans were important for apical 
targeting [18, 19]. Glycosylation is not a prerequisite for catalytic activity or dimerization [12]. 
However, the stability of the cysteine-rich region of DP4 is proposed to be of importance for 
dimer formation [8]. 
 
 
 
Figure 1: Schematic representation of wild type rat DP4 deduced from its primary structure.  
Modified after Fan et al. [14]; Y-shaped structures represent N-glycans; SH, cysteine residue; catalytic 
triad: Ser, Asp, His; numbers represent the amino acid position; magenta, cytoplasmic tail; pink, 
transmembrane domain 
 
In humans, the cysteine-rich domain is involved in ADA binding [20]. Moreover, Dobers et al. 
[8] showed via cysteine point mutations in rat DP4 that the cysteine residues 326, 337, 445, 
448, 455, 473, and 552 are essential for correct folding and intracellular trafficking of DP4. 
Two non-covalently connected independent monomers form the functional DP4 homodimer, in 
which again the active sites of both monomers are connected via electrostatic interactions [21]. 
Homodimerization is essential for the enzyme activity of DP4, whereas the monomeric form 
on its own has no enzyme activity [22-26]. The molecular weight of the DP4 monomer 
depends on the species, the origin/type of tissue, and the level of glycosylation. It differs 
around 110 kDa to 150 kDa in mammals [27-29]. There is an initially synthesized precursor 
form with a molecular weight of 103 kDa in rat hepatocytes that is further processed to the 
mature form of 109 kDa during the intracellular transport [30].  
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While the extracellular part of DP4 has been approximately divided into the three regions on 
basis of the amino acid sequence (Fig. 1), cryo-transmission electron microscopy and crystal 
structures revealed a new three-dimensional (3D) structure for human DP4. This 3D structure 
gives precise details about the amino acids that compose functionally different domains. Thus, 
analysis of the crystal structure of DP4 revealed that the extracellular part of each DP4 
monomer consists of two domains (Fig. 2), the catalytically active /-hydrolase domain 
(amino acids 39-51 and 506-766) – that is located closest to the membrane – and an eight-
bladed -propeller domain (55-497) [31, 32]. The catalytic site is located in a large cavity 
formed between the /-hydrolase domain and the propeller domain. Both domains are 
reported to participate in inhibitor binding [32].  
1.2. Distribution of DP4 
DP4 is highly conserved among different species [31] and DP4 expression in rat tissues does 
not significantly differ from expression in humans. The membrane-bound form of DP4 is 
ubiquitously expressed with different levels in tissues like kidney, lung, adrenal gland, 
intestine, liver, spleen, testis, and brain. Endothelial and epithelial DP4 is localized on the 
apical cell membrane [33]. The abundant expression on endothelial cells, especially in blood 
vessels and capillaries [34], enables a close contact to hormones, chemokines, and cytokines 
that are circulating in the blood. There is a soluble form of DP4 that lacks the transmembrane 
domain [35, 36] and which can be found in plasma and at low levels in the cerebrospinal fluid 
(CSF) [35], urine, and seminal fluid [37, 38]. The origin of soluble DP4 so far is unknown. 
However, shedding of the membrane-bound form via other proteases is a proposed mechanism. 
Furthermore, DPPIV/CD26 is expressed on cells of the immune system and here, especially on 
activated T-helper cells and B lymphocytes [39-41], activated NK cells [42], and subsets of 
macrophages [43]. In the adult central nervous system (CNS) DP4 has contact with 
neuropeptides mainly in the CSF but also via the blood-brain barrier (BBB). DP4 is primarily 
found in the circumventricular organs (CVOs) and on leptomeningeal cells, in brain capillaries 
and ependymal cells [44, 45]. DP4 positive neurons are only found in the fetal brain; they 
decrease during development [44, 46-49]. In the peripheral nervous system (PNS), DP4 is 
located in the perineurium and Schwann-cells [50].  
The overall presence of DP4 enables the peptidase to act on substrates and immune cells in 
body fluids underlining its relevance in physiological, psychological and immunological 
processes [51]. Aberrant DP4 levels have been reported as clinically relevant for various 
diseases [24, 52-54]. For example, patients with major depression [55] or schizophrenia [56] 
Introduction  14 
show a decrease in serum DP4-like activity, whereas an increase in DP4-like serum activity 
was reported in patients with hyporectic eating disorders like anorexia and bulimia nervosa 
[54, 57]. Furthermore, altered DP4 levels are reported in autoimmune diseases like rheumatoid 
arthritis [58-60] or HIV/AIDS [61] as well as in allograft rejection [62] or pregnancy [63].  
1.3. Functional role of DP4  
– enzymatic activity, extracellular matrix binding, and T cell activation 
The importance of DP4 is derived from various biological processes and the multifunctional 
role in mammalian organisms is not only a result of enzymatic activity but also of cell adhesion 
and T cell activation processes (Fig. 2).  
Independently from its enzymatic activity, DP4 shows high affinity for the matrix proteins 
collagen and fibronectin. It could be shown that DP4 initiates the adhesion of rat hepatocytes 
on a collagen matrix [64, 65]. Furthermore, interactions of rat DP4 with fibronectin could be 
demonstrated [66]. The cysteine-rich domain of DP4 is reported to interact with collagen and 
fibronectin of the extracellular matrix (ECM) and two separate binding sites for collagen and 
fibronectin were proven in this domain [2, 67, 68].  
DP4 acts as costimulatory surface molecule, influences T cell activity, and modulates 
chemotaxis [69]. Due to its enhanced expression on activated lymphocytes, DP4/CD26 is 
originally described as a T cell activation marker, but is now regarded as a general marker of 
cellular activation. DP4/CD26 is considered to play a role in T cell activation [20, 70, 71] and 
proliferation via costimulation [72-76]. Maximal T cell activation requires an antigen-specific 
stimulation of the TCR/CD3 complex, provided by a MHC/peptide complex, and a 
costimulatory signal. In this context, caveolin-1 is actually discussed to act as costimulatory 
ligand for DP4/CD26. Ligation of CD26 by caveolin-1 induces upregulation of CD86 – the 
ligand of CD28 – via NF-B activation. CD28 then mediates costimulation and potentiation of 
T cell proliferation in a TCR/CD3-dependent manner [77, 78]. 
DP4 disposes of major influence in body functions via its protease activity. As serine 
exopeptidase, DP4 regulates various physiological processes by cleaving Xaa-Pro dipeptides 
from the N-terminus of oligo- and polypeptides. According to Schechter and Berger [79], 
residues in a peptide substrate are called P1, P2, P3.... Pn counting from the scissile bond toward 
the N-terminus and P1’, P2’, P3’... Pn’ counting toward the C-terminus. Originally, DP4 was 
considered to cleave specifically after proline, or with less efficiency after alanine, at P1 
position. Meanwhile, the substrate spectrum has been enlarged, thus, other amino acids like 
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valine, glycine, and serine for example are accepted in penultimate (here, P1’) position – 
however, with strongly reduced catalytic efficiency [80, 81]. Numerous biologically active 
peptides like neuropeptides, peptide hormones and chemokines possess evolutionary conserved 
proline-rich regions in their sequences [82, 83]. These proline residues serve as proteolytic 
processing regulatory element and prevent from unspecific proteolysis.  
 
 
Figure 2: Schematic representation of the structure of the DP4 homodimer with respect to its 3D 
composition and to its main functional role: / hydrolase domain and the eight-bladed -propeller 
domain with corresponding numbering of amino acids (aa) (according to human DP4); yellow, plasma 
membrane; red, functions of DP4; Xaa, variable amino acid  
 
As sole natural imino acid, proline connotatively influences secondary and tertiary structures of 
peptides and thus controls their biological activity [84]. Regulation of this activity can take 
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place via proline specific peptidases. In case of many regulatory peptides, it could be shown 
that they are substrates of DP4 [2, 51, 69]. Cleavage of N-terminal dipeptides leads to 
activation or inactivation of the substrates and thus prevents the binding at specific receptors 
and enables the regulatory intervention in biological cascades. Furthermore, cleavage by DP4 
also makes substrates accessible for further or for total degradation by other peptidases (Fig. 
2). 
1.4. Structural and functional homologues of DP4 
For many years DP4 was believed to be a unique cell membrane protease cleaving Xaa-Pro 
dipeptides from the N-terminal end of peptides. Subsequently, other “DP4 activity and/or 
structure homologues” termed DASH have been discovered. These proteins are grouped on the 
basis of having an associated DP4-like enzymatic activity with or without much structural 
homology, or they reveal structural similarity but are enzymatically inactive (dipeptidyl 
peptidase 6 (DP6) and 10 (DP10)). The DASH protein family comprises, for example, 
fibroblast activation protein  (FAP-) alias seprase, quiescent cell proline dipeptidase (QPP) 
alias dipeptidyl peptidase 2 (DP2), dipeptidyl peptidase 8 (DP8), dipeptidyl peptidase (DP9), 
attractin, N-acetylated -linked acidic dipeptidases (NAALADases) and thymus-specific serine 
protease [85, 86]. These peptidases should be taken into account when conducting tests based 
on DP4-like activity and inhibitor studies. 
1.5. Substrates of DP4 and their physiological impact 
Whereas former experiments concentrated on the question which peptide hormones, 
chemokines, and neuropeptides are cleaved by DP4, later experiments focused on its biological 
function in vivo. Therefore, DP4 specific inhibitors and DP4 negative animal models were 
useful. Exogenously administered inhibitors of DP4 prolong the biological half-life of DP4 
substrates, with several of them being highly important clinical and pharmaceutical targets for 
drug development. 
In vivo and in vitro experiments demonstrated the truncation of many substrates by DP4. N-
terminal cleavage of the peptide hormones glucose dependent insulinotropic polypeptide (GIP), 
glucagon like peptide 1 and 2 (GLP-1, GLP-2) leads to their inactivation. GIP and the active 
form of GLP-1 – GLP-1(7-36) – stimulate, in response to blood glucose increment, the release 
of insulin from pancreatic beta-cells. Inhibition of DP4 increases the amount of intact incretins 
like GLP-1 and GIP, improves their insulinotropic effect, and has been proposed as being a 
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valid therapeutic approach for lowering glucose levels in type 2 diabetes or other disorders 
involving glucose intolerance [51]. Treatment of diabetes type 2 is of major interest and a 
present field of research. Actually, new pharmaceuticals acting as DP4 inhibitors are 
introduced to the market. 
Endomorphin-2 is an endogenous opioid that is abundantly present in the cortex of the human 
brain. It has a high affinity for the  (morphine) opioid receptors that produce analgesia. The in 
vivo inactivation of endomorphin-2 by DP4 was demonstrated in rats and central inhibition of 
DP4 leads to enhanced analgesic actions of exogenous endomorphin-2 [87]. Another substrate 
is -casomorphin (BCM), which is derived from the milk protein casein from mammals. It is 
converted by DP4 into further -casomorphin fragments [88-91]. -casomorphins have potent 
opioid activity and therefore are referred to as exorphins or formones (food hormones). 
Casomorphins can influence the digestion and intestinal absorption processes. They extend the 
storage period of food in the gastrointestinal tract and influence the postprandial metabolism 
via stimulation of insulin and somatostatin secretion [92].  
Substance P (SP) is a widespread neuropeptide that originates from spinal ganglia. This peptide 
has a well-established role in immunity and induces the release of inflammatory mediators 
from mast cells and causes an increase in vascular permeability. SP is – together with other 
tachykinins – responsible for nociceptive transmission from the peripheral to the central 
nervous system [93, 94]. Additionally, DP4 is supposed to enhance nociception by processing 
SP to a more potent derivate (SP3-11; SP5-11) [95] in combination with inactivating potent 
analgesic μ-opiate receptor agonists and other DP4 substrates [53]. Another substrate is the gut 
hormone peptide YY (PYY) [96, 97] which is secreted from the endocrine L cells of the gut 
[98]. It is found at low levels in the small intestine with concentrations increasing distally 
throughout the gut to reach maximum concentration in the rectum. Circulating PYY levels are 
low in the fasting state and rapidly increase postprandially. N-terminal truncation of PYY1-36 by 
DP4 results in PYY3-36 which is a potent physiological regulator of satiety. 
1.6. NPY – a DP4 substrate of high relevance 
NPY was discovered and isolated in 1982 by Tatemoto [99]. Together with the pancreatic 
polypeptide (PP) and PYY, NPY belongs to the pancreatic polypeptide (PP-fold) family. 
Common characteristics of this family are a tyrosine-rich sequence of 36 aa and a C-terminal 
tyrosineamide residue that is essential for biological activity. The name of NPY and PYY is 
due to the presence of a large number of tyrosine residues – abbreviated by the letter Y in the 
single letter amino acid code – including both ends of the molecule. 
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The evolutionary high conservation of NPY (the sequence of human and rat NPY is identical) 
supports the idea of being a key mediator in the regulation of physiological processes. As 
neuropeptide, NPY acts in the CNS and PNS and displays a large array of functions [100-102]. 
NPY is the most abundant neuropeptide in the brain [103] and it is preferentially expressed in 
interneurons [104, 105]. Particularly high levels of NPY-like immunoreactive material are 
found in the hypothalamus, the septum, the nucleus accumbens, the periaqueductal gray, and 
the locus coeruleus [103, 105, 106] whereas moderate levels can be detected in the amygdala, 
the hippocampus, cerebral cortex, basal ganglia, and the thalamus [103, 107]. Furthermore, 
NPY is broadly distributed via NPY-containing cell bodies and is found in fibres of organs like 
pancreas, intestinal tract, heart, thyroids, kidney, lung, and gonads [103]. The localization of 
nerve terminals and cell bodies suggests a wide-ranging role for NPY in behaviour and 
physiology.  
NPY influences feeding behaviour and thus the body weight regulation [108, 109]. The 
influence of NPY on the inhibition of adipolysis and on increased lipoproteinase activity leads 
to an increased storage of fat [110]. Based on this, an important role in pathophysiology of 
obesity and diabetes is attributed to NPY. 
1.6.1. NPY and NPY receptor subtypes 
In rat, the peptides of the PP family activate a heterogeneous population of at least four G 
protein-coupled receptors (GPRs; Y1, Y2, Y4, and Y5) that differ in selectivity [111-113]. NPY 
and PYY are both processed by DP4 via N-terminal dipeptide cleavage from a molecule of 36 
aa length (NPY1-36/PYY1-36) to NPY3-36 /PYY3-36 and thus exhibit changed receptor specificity. 
The (3-36) derivates show a reduction in Y1 receptor affinity, whereas their affinities are not or 
scarcely reduced at the Y2 and Y5 receptors which makes them selective for Y2 and Y5 
receptors relative to Y1 receptors [114]. The different NPY receptors that are involved in 
activating processes in rat and human are presented in table 1.  
Further discovered and discussed receptor subtypes are the Y3 receptor – which is 
pharmacological detectable, however, not yet cloned – the Y6 receptor that is non-existent in 
rats and non-functional in humans and other primates, and the Y7 receptor which is not found 
in mammals. A very recently discovered potential NPY receptor is the G protein-coupled 
receptor (GPR)83 [115].  
Originally, the subdivision of NPY receptors comes from the observation that C-terminal 
fragments of NPY or PYY, e.g. NPY 13-36, can mimic some NPY responses while some others 
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cannot [116]. This has led to the proposal that receptors that are only activated by the 
holopeptides are designated Y1, whereas those that are activated by the holopeptides and the C-
terminal fragments are designated Y2. Despite the synthesis of numerous C-terminal fragments, 
the (3-36), (13-36), and (18-36) fragments of NPY and PYY are most frequently used without 
apparent advantages between them [113]. C-terminal NPY fragments are still useful to 
discriminate Y1 and Y2 receptors, but they are not selective for Y2 receptors since they can also 
activate Y5 receptors at similar concentrations [114]. Therefore, synthesized forms of NPY and 
PYY exist in which different amino acids are substituted (e.g. [Pro34]NPY).  
Table 1: Functional NPY receptor subtypes in rat/human 
Receptor Y1 Y2 Y4 Y5 GPR83/GIR 
Major 
occurence 
periphery 
hypothalamus 
brain 
hippocampus 
intestine 
colon 
hypothalamus brain, thymus; 
selectively up-
regulated surface 
molecule by 
Treg cells 
Related 
action 
anxiolysis,  
food intake, 
vasoconstriction, 
nociception 
memory, 
epilepsy,  
secretion,  
food intake? 
gastro-
intestinal 
regulation 
food intake?,  
epilepsy? 
orphan G 
protein-coupled 
receptor 
Agonist 
order of 
potency 
NPY  PYY >> PP NPY  PYY 
>> PP 
PP > NPY = 
PYY 
NPY  PYY  
PP 
NPY  PYY >> 
PP 
Selective 
agonists 
[Leu31, Pro34]NPYa, 
[Pro34]NPYa, 
[Leu31, Pro34]PYYa, 
[Pro34]PYYa 
NPY3-36
b,  
PYY3-36
b,  
NPY13-36
b, 
PYY13-36
b 
PP [Ala31, 
Aib32]NPY 
NPY3-36
 b, PYY3-
36
 b 
 
a selective relative to Y2 receptors 
b selective relative to Y1 receptors 
modified after Cabrele et al., 2000 [111], and Alexander et al. 2007 [117]; Treg cells, regulatory T cells 
 
NPY is involved in various physiological and behavioural processes that are mediated via DP4 
cleavage [1, 51, 118]. Activation of the Y1 receptor induces a long-lasting vasoconstriction and 
enhances the effects of vasoconstrictive substances like angiotensin II or noradrenaline – 
influenced by NPY [119-121]. Anxiolysis and sedation are mediated within the CNS and are 
modulated via the Y1 receptor [112, 122-124]. In this context, NPY has a sedative [124-126] 
and an anxiolytic effect [112, 127, 128]. Furthermore, mainly the Y1 receptor seems to be 
involved in regulation of food up-take, although the Y5 receptor is discussed as appetite 
Introduction  20 
receptor [114, 129-131]. The Y2 receptor has also been focussed in regard to its food intake 
regulation [132-134]. NPY has an antinociceptive effect that is mediated via Y1 receptors. 
Various effects that are mediated via the Y2 receptor are based on the inhibition of the release 
of neurotransmitters. Thus, NPY inhibits the release of glutamate in the CNS as well as the 
release of noradrenaline and acetylcholine in the PNS via presynaptical activation of the Y2 
receptor. NPY enhances the memory retention by activation of the Y2 receptor [135-137] and 
regulates the circadian rhythm of rodents [138-143]. 
1.6.2. Role and sources of N-terminally truncated NPY3-36 and PYY3-36 
peptides 
The power of DP4, to act as modulator of important regulatory processes via N-terminal 
truncation, gives rise to think about the precise localization where these actions may take place. 
Different factors that determine these regulatory processes are amongst others the amount and 
localization of the corresponding substrate receptors, substrate concentration, kinetic 
parameters, and the consequence of action (e.g. activation, inactivation, or degradation). In line 
with this, sources of N-terminally truncated NPY, PYY, and further substrates are of highest 
interest. An important role for N-terminally truncated PYY has been suggested when 
Batterham et al. [144] reported on the potent feeding regulatory effects of PYY3-36. However, 
controversies arose when a number of laboratories could not repeat the core observation that 
PYY3-36 suppressed food intake in rodents.  
Although the detailed comparison of methodologies and protocols has led to several 
hypotheses, the reasons for these discrepancies are unknown. Nonetheless, publications of 
positive and negative results on pharmacological effects and endogenous roles of PYY in 
energy balance have triggered new studies with increased attention to these details and 
experimental conditions [145]. Unfortunately, the source of this truncated peptide remained 
unknown. Despite the reported release of PYY1-36 into the circulation, it seems to be unlikely 
that such important effects that are ascribed to PYY3-36, are primarily due to „non-specif“ 
cleavage in the plasma. We therefore hypothetized that PYY1-36 and also NPY1-36 are truncated 
intracellularly by DP4 and investigated this in co-transfection experiments. 
1.7. Animal models of DP4 deficiency 
The overall importance of the ubiquitously distributed DP4 is not only due to its involvement 
in various diseases and immune functions but is reflected by its broad range of substrates – 
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each being individually involved in biological cascades. Animal models serve for a better 
understanding of the role and function of D4. Therefore, former investigations concentrated on 
the charaterization of the DP4 deficient model of F344 rats – including the two DP4 deficient 
substrains F344/DuCrjSvH-Dpp4m and F344/Crl(Wiga)SvH-Dpp4m, previously named 
F344/DuCrj(DPPIV-) and F344/Crl(Ger/DPPIV-) – that were compared to wild type rats 
F344/Crl(USA) or F344/Ztm [146-148].  
It has been shown that in rat Dpp4 is located on rat chromosome 3 (RNO3) and is inherited in a 
semi-domant mode [146]. Furthermore, these rats are DP4 deficient due to a point mutation in 
the Dpp4 gene – a transition from G to A at nucleotide 1897 that leads to substitution from Gly 
to Arg in the catalytic center of the enzyme at amino acid position 633 [30]. While normal 
levels of DP4 mRNA are produced [149], the mutation causes a conformational change, 
leading to a rapid degradation in the endoplasmic reticulum [30] and thus, leading to a total 
loss of DP4 activity [30]. DP4 deficiency leads to a prolonged half-life of DP4 substrates.  
Consequently, animals of the former model were phenotyped by our group mainly with respect 
to behavioural and physiological aspects that were attributed to differential degradation 
processes of various substrates. Although both DP4 deficient F344 substrains bear the identical 
mutation, they differ in some results of phenotyping [146, 147]. Due to this fact and the point 
that the different rat substrains were originally obtained from different Charles River facilities, 
it is very likely that differences in the genetic background might have an influence on those 
differential outcome measures in F344/DuCrjSvH-Dpp4m and F344/Crl(Wiga)SvH-Dpp4m rats. 
In addition, microsatellite analysis revealed differences in the genetic background between the 
mutant and the various non-deficient F344 substrains apart from Dpp4 (unpublished data). To 
yield a homogenous genetic background for precise investigation and to enhance behavioural 
and physiological differences that were found between the DP4 deficient F344 substrains and 
the F344 wild type substrain, the new DP4 deficient congenic DA substrain DA.F344-
Dpp4m/SvH was developed. Thereby, the mutation of the F344/Crl(Wiga)SvH-Dpp4m substrain 
was transferred onto the genetic background of DA/Ztm rats. The development was speeded-up 
with help of marker-assisted selection. Wild type DA/Ztm rats show a nearly two-fold 
expression of DP4-like activity in comparison to wild type F344/Crl(USA) rats. Thus, we 
expect differences between DP4 deficient and DP4 wild type rats to be more distinct.  
A further aspect that requires and justifies this new congenic animal model next to the above 
mentioned advantages of high DP4-like activity and the homogenous genetic background, is 
for example, the possibility of testing the specificity of DP4 inhibitors – wherefore the 
homogenous genetic background is essential. In addition, the species-specific contribution of 
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Rattus norvegicus can back-up findings of the existing Dpp4tm1Nwa mouse model (CD26 
knockout (KO)) but importantly, it can also reveal discrepancies. Interestingly in this context 
are also studies with NPY transgenic rats [150, 151] that over-express prepro NPY mRNA or 
NPY KO mice. The latter revealed contradictory results to effects that were ascribed to NPY 
[152-154]. However, as these “classical” KO mice represent germ-line KO mice, a life-long 
compensation for the lack of NPY might explain why the phenotype is less pronounced. This 
suggests that there is a need for inducible NPY and NPY receptor KO mice. Furthermore, this 
clearly demonstrates that any kind of approach gives its own answer and reminds that various 
approaches help to clarify regulatory functions and networks. 
1.8. Aims of the present thesis 
The aim of the present study is to further investigate and understand the role of DP4 in vitro 
and in vivo with special emphasis on its interaction with NPY. Therefore, we focused in a first 
attempt on the intracellular transport of DP4 and its substrate NPY to search for possibilities of 
fine-tuning mechanisms in intracellular regulation of NPY1-36/NPY3-36 levels, caused by DP4. 
Additionally, the involvement of structural and functional homologues of DP4 was discussed 
with respect to their potency to control endogenous NPY levels [155].  
A second step was the investigation of DP4 deficiency in a new animal model on the 
homogeneous genetic background of DA rats. We conducted a comprehensive phenotyping 
strategy based on endocrine and immunological as well as on behavioural and physiological 
aspects. We focused on the latter, since behaviour and physiology are likely to be regulated by 
DP4 substrates, especially by NPY. These studies were made to detect fields of impact and to 
appraise possible consequences of the nowadays actually discussed DP4 inhibitors. 
Furthermore, our data serve to support theories and hypotheses of the function of DP4 from 
findings in the previously used animal model of DP4 deficient F344 rats and will be helpful for 
the further use of the novel animal model for DP4 deficiency.  
The last field of our studies focused on the differential pain perception/processing in DP4 
deficient and wild type F344 and DA substrains, which relates to the differential stress-
responsiveness in DP4 deficient animals. These variable findings in stress responsiveness 
result in the phenomenon of differential stress-induced analgesia. Here, DP4 deficient congenic 
DA rats were compared with spontaneous mutant DP4 deficient F344 rats in a genetically and 
pharmacological based approach. The modulation of stress-induced analgesia in DP4 deficient 
animals was compared with effects resulting from pharmacological inhibition of DP4. This 
additional pharmacological approach comprises the analysis of DP4 deficient and wild type 
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F344 rat substrains after i.c.v. application of either NPY or the DP4 inhibitor isoleucyl-
thiazolidide (Ile-Thia). 
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Abstract 
N-terminal truncation of NPY has important physiological consequences, because the truncated 
peptides lose their capability to activate the Y1-receptor. The sources of N-terminally truncated 
NPY and related peptides are unknown and several proline specific peptidases may be 
involved. First, we therefore provide an overview on the peptidases, belonging to structural and 
functional homologues of dipeptidyl peptidase 4 (DP4) as well as aminopeptidase P (APP) and 
thus, represent potential candidates of NPY cleavage in vivo. Second, applying selective 
inhibitors against DP4, DP8/9 and DP2, respectively, the enzymatic distribution was analyzed 
in brain extracts from wild type and DP4 deficient F344 rat substrains and human plasma 
samples in activity studies as well as by matrix assisted laser desorption/ionisation-time of 
flight (MALDI-TOF)-mass spectrometry. Third, co-transfection of Cos-1 cells with Dpp4 and 
Npy followed by confocal lasermicroscopy illustrated that hNPY-dsRed1-N1 was transported 
in large dense core vesicles towards the membrane while rDP4-GFP-C1 was transported 
primarily in different vesicles thereby providing no clear evidence for co-localization of NPY 
and DP4. Nevertheless, the review and experimental results of activity and mass spectrometry 
studies support the notion that at least five peptidases (DP4, DP8, DP9, XPNPEP1, XPNPEP2) 
are potentially involved in NPY cleavage while the serine protease DP4 (CD26) could be the 
principal peptidase involved in the N-terminal truncation of NPY. However, DP8 and DP9 are 
also capable of cleaving NPY, whereas no cleavage could be demonstrated for DP2. 
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2.1. Introduction 
N-terminally truncated derivates of NPY and PYY are involved in several physiological 
functions. In contrast to the full-length peptide, truncated forms starting at position 2 or 3 lose 
their efficacy at the Y1-receptor but they are active especially at the Y2-receptor. For a better 
understanding of this differential regulation detailed knowledge on the sources as well as on 
the local and systemic regulation of NPY3-36 and PYY3-36 levels is indispensable. In fact, NPY3-
36 and PYY3-36 have been shown to play a role in energy metabolism via inhibition of exocrine 
pancreas function [32] or other feeding associated processes [36, 58, 74] and probably are 
involved in several other as yet to be discovered physiological functions. These regulatory 
processes are closely dependent on the expression and function of DP4-like peptidases due to 
their capability in hydrolyzing the post-proline bond between position 2 and 3 of NPY and 
PYY. 
In a series of studies we characterized F344 rat substrains, which are deficient for DP4 and 
which exhibit improved glucose tolerance, differential weight gain, as well as differential 
immune functions [46]. In addition, these DP4 deficient substrains exhibit a phenotype of 
reduced stress-responsiveness and anxiety [49], and were used to demonstrate that central 
application of NPY results in more potent anxiolytic-like and sedative-like effects when 
injected intracerebroventricularly (i.c.v.) in deficient animals [48]. Recently, we also found an 
increased potency of i.c.v. NPY with regard to pain perception in DP4 deficient substrains 
[47]. These findings are most likely mediated by prolonged activation of central NPY Y1-
receptors, which is the predominant anxiolytic-like acting receptor type of NPY [50].  
DP4 (CD26) is presumably the peptidase most frequently involved in N-terminal truncation of 
NPY [64]. From a theoretical point of view, however, other DP4-like peptidases may also be 
involved in NPY cleavage. In this review we summarize recent developments in the field of 
DP4 functional homologues and – in addition – present initial data investigating intracellular 
localization of DP4 and NPY using confocal analysis of Npy/Pyy and Dpp4 co-transfected 
COS-1 cells as well as cleavage of NPY by functional homologues of DP4. 
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2.2. Review on DP4-like structural and functional homologues 
2.2.1. Classification of peptidases  
Enzymes in general are classified into six enzyme classes due to their catalytic reaction by the 
code system IUPAC and IUBMB. Peptidases are also named peptide hydrolases, based on their 
capability to hydrolyse peptide bonds and belong to the subclass 3.4, which is further sub-
divided into 14 sub-subclasses, depending on the type of active site of the enzymes and/or the 
kind of the preferred substrate. Furthermore, a new structure-based classification system, called 
MEROPS, was introduced by Neil D. Rawlings and Alan J. Barett in 1993, assigning 
peptidases with statistically significant similarities in amino acids to a family, whereas 
homologous families are grouped together into a clan [78].  
In the following, we especially focus on the potential NPY degrading aminopeptidases, the 
members of the Dpp4 gene family, the functional homologues of DP4, DP2 and the X-prolyl 
aminopeptidases. The classification of these enzymes within the different systems, their 
expression, and potential physiological role is summarized in table 1. 
Dipeptidyl peptidase 4 (DP4) as representative member of the DP4 gene family is the best 
understood proteinase with the rare capability of hydrolysing post-proline bonds [29]. DP4 
comprises 766 amino acids and is a type II transmembrane glycoprotein that has also a soluble 
shedded form [65]. The multifunctional peptidase has a molecular weight of 110 kDa and is 
active as a homodimer. It is known to cleave peptide hormones such as GLP-1, GLP-2, GIP, 
glucagons; neuropeptides including NPY, substance P, endomorphin 1 and 2 as well as various 
chemokines. Thus it is involved in glucose homeostasis, food up-take, anxiety, stress, 
cardiovascular, nociception and chemotaxis. Furthermore, it functions as an extracellular 
adhesion molecule by binding to collagen, fibronectin and plasminogen. In addition, it is 
implicated in various immune responses via its interaction with several immunological 
molecules such as ADA or CD45 and acts as a marker for activated T cells [11, 39, 53]. It is 
ubiquitously distributed with the highest expression in kidney, lung, liver and small intestine 
whereas low expression is found in brain, heart and skeletal muscle. According to kinetic 
analysis, DP4 has the highest selectivity for NPY and PYY [9, 30, 37, 40]. The human gene 
location of DP4 is 2q24.2.  
Fibroblast activation protein   (FAP) alias seprase is a type II transmembrane protein. It 
consists of 760 amino acids and forms a 170 kDa homodimer [27]. Like DP4, the monomeric, 
N-glycosylated 97 kDa subunits are proteolytically inactive, thus their proteolytic activities are 
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dependent upon subunit association [75]. Furthermore, FAP can form a heterodimeric 
membrane-bound proteinase complex with DP4 [83]. In comparison to DP4, FAP displays 
only a hundredth of post-proline dipeptidyl aminopeptidase activity [25]. However, in addition 
to its DP4-like activity, it exhibits also post-proline endoproteolytic activity specific for …Xaa-
Gly-Pro-Yaa… sequences [24]. Thus, it has been described as a gelatinase and collagenase type 
I, involved in wound healing and metastasis. Unlike DP4, protein expression of FAP is found 
on pathological tissue such as epithelial cancer, wounds and stellate cells in liver cirrhosis [28]. 
A soluble form has recently been found in serum where it was shown to cleave alpha2-
antiplasmin [55, 56]. So far, there have been no reports on the cleavage of NPY by FAP, 
though its post-proline dipeptidyl aminopeptidase activity is expected to be minor and no 
endoproteolytic hydrolysis should occur. The human gene localization is 2q23, close to the 
Dpp4 gene and therefore gene duplication has been suggested [1]. 
Dipeptidyl peptidase 8 (DP8) consists of 882 amino acids and has a molecular weight of 100 
kDa. Although DP8 has previously been reported to be monomeric, recent data gave strong 
evidence for a dimeric structure with a suggested molecular weight above 200 kDa [9]. So far, 
it has been suggested to be located in the cytoplasm as a soluble protein and up to now, there 
has been no evidence for any secretion [2, 15]. Using several chromogenic substrates, [77] DP8 
was shown to display post-proline dipeptidyl aminopeptidase activity similar to that of DP4. 
The well-known natural substrates of DP4, NPY and PYY, are both also cleaved by DP8, 
however with lower efficiency compared to DP4. In fact, while NPY was demonstrated to be 
the best substrate for DP8, PYY had a very long half life [9].This would imply that the 
specificity is extended to P´1, which differ in serine and isoleucine for NPY and PYY, 
respectively. DP8 is distributed ubiquitously with its highest expression in testis and brain. 
Furthermore, it is up regulated in activated lymphocytes [2]. However, its physiological 
function is presently unknown and still awaits further studies. The human gene localization is 
15q22.  
Dipeptidyl peptidase 9 (DP9) has previously been reported to be active as a cytosolic 
monomer comprised of 863 amino acids with a molecular weight of approximately 100 kDa 
[4]. Further ORFs of 2913 bp [28] and 3006 bp [4] have been described. Recently, a new DP9 
variant with another start site in a prolonged ORF leading to an enzymatically active protein of 
892 amino acids has been published by Bjelke et al. [9]. This variant was shown to be active as 
homodimer with an estimated molecular weight above 200 kDa, whereas no activity could be 
detected for the 863 amino acid variant [9]. Using several chromogenic substrates, Qi et al. 
(2003) and Ajami et al. (2004) illustrated post-proline dipeptidyl aminopeptidase activity for 
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DP9 similar to that of DP4. Like DP8, DP9 is able to cleave NPY and PYY, though with a 
lower efficiency compared to DP4. Likewise, NPY, was shown to be the best natural substrate 
for DP9, whereas PYY exhibited the longest half life of the investigated substrates [9]. DP9 is 
ubiquitously distributed, with its highest expression in liver, heart and skeletal muscle [4, 68, 
77]. Its physiogical function is not known so far. The localization of the human gene is 
19p13.3. Due to their shortest gene size, lowest number of exons and the active site being 
located on one exon in comparison to DP4 and FAP, DP8 and DP9 have been suggested to be 
the most ancient DP4-like enzymes [1, 2]. It should be mentioned that side effects obtained 
during the course of toxicological studies of a non-selective inhibitor were due the inhibition of 
DP8 and/or DP9 [54].   
The two other members of the DP4 gene family are not involved in NPY processing, because 
they lack any DP4 activity due to the absence of the catalytic serine and are therefore 
designated with dipeptidyl peptidase like protein 1 (DPL1) and 2 (DPL2). Both of them are 
type II membrane-bound glycoproteins, suggested to interact with the voltage-gated potassium 
channel Kv4. While DPL1 is exclusively expressed in the brain, DPL2 is found in brain, 
pancreas and adrenal gland [1, 14, 15, 28, 77, 86, 91].  
Dipeptidyl peptidase II (DP2) alias quiescent cell proline dipeptidase (QPP), belongs to the 
family S28. The soluble serine protease possesses a proform and has a length of 492 amino 
acids [16, 87] with a molecular weight of 58 kDa. Dimerization is required for the catalytic 
activity and occurs via a leucine zipper motif, which is novel for proteases. The homodimer is 
located in cellular vesicles that are distinct from lysosomes [57]. Using chromogenic 
substrates, DP2 displays post-proline dipeptidyl aminopeptidase activity similar to DP4, 
however with an acidic pH optimum of 5.5 [59]. Hydrolysis of peptides is highly restricted to 
size. While DP2 readily hydrolyses tripeptides, its activity decreases rapidly with increasing 
chain length of peptide. Thus, it was shown to cleave only fragments of substance P1-4, 
bradykinin1-3 or bradykinin1-5 [13, 67]. DP2 is ubiquitously distributed with high expression in 
kidney, brain, testis and heart [21, 31]. Since it was previously thought to be a lysosomal 
enzyme, its physiological function to date is unknown. The human gene localization is 9q34.3.  
Four enzymes have previously been acclaimed to exhibit DP4-like activity, including attractin 
(DPPT-L) and N-acetylated alpha-linked acidic dipeptidases I, II and L (NAALADase I, II 
and L) [20-22] [71, 84]. However, this is controversially discussed and there are also several 
hints from a thorough analysis of serum DP4 activity for attractin [23] and kinetics of purified 
recombinant NAALADase II, respectively [7] that these proteins exibit no DP4-like activity. 
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Furthermore, NPY is also truncated to NPY2-36 by prolyl aminopeptidases, belonging to 
family M24 [43, 60, 62, 63]. There are two X-prolyl aminopeptidases, located on different 
genes. 
X-prolyl aminopeptidase 1 (XPNPEP1) is a soluble cytosolic protein, lacking the 
hydrophobic signal sequence at the N-terminus and the GPI-anchor at the C-terminus [17]. It is 
a homodimer, comprised of 623 amino acids with a molecular weight of 71 kDa per subunit 
[88]. The enzyme contains a putative proton shuttle 5 and divalent metal ligands [85]. Due to 
its proline specificity, it is suggested to hydrolyse peptide hormones, neuropeptides and 
tachykinins. Unlike DP4, it is able to hydrolyse peptides containing two consecutive prolines 
in penultimative N-terminal position (Xaa-Pro-Pro-Yaa…), such as bradykinin [33, 34, 60]. 
XPNPEP1 is ubiquitously distributed, with its highest expression in pancreas, followed by 
heart and muscle. Only XPNPEP1 but not XPNPEP2 is found in the brain [88]. The human 
gene location is 10q25.3.  
X-prolyl-aminopeptidase 2 (XPNPEP2) is a GPI-anchored membrane-bound aminopeptidase 
encoding for 673 amino acids with a molecular mass of 75.5 kDa. XPNPEP2 is expressed in 
kidney, lung, heart, placenta, liver, small intestine, and colon, but not in brain, skeletal muscle, 
pancreas, spleen, thymus, prostate, testis, ovary, or leukocytes [89]. It hydrolyses NPY and 
bradykinin [69, 70] and is suggested to be involved in cardiovascular diseases [3, 10]. The 
human gene localization is Xq25.  
Based on this compelling theoretical evidence, and the fact that vesicular localization of 
soluble DP4 has already been observed in -cells of islets of Langerhans [35, 76], we started to 
investigate a possible co-localization of DP4 and NPY/PYY intracellularly. 
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2.3. Materials and methods 
Animals 
While the F344/Crl(Por/98), also named F344/Crl(USA), and F344/Ztm rat substrains exhibit a 
DP4 wild type-like phenotype, the substrain F344/Crl(Wiga)SvH-Dpp4m is deficient for DP4. 
F344/Crl(Por/98) and F344/Crl(Wiga)SvH-Dpp4m substrains were originally obtained from 
Charles River in 1998 and are now further inbred. 
Tissue extraction 
Brains, obtained from F344/Crl(Por/98) and F344/Crl(Wiga)SvH-Dpp4m rats, were extracted 
with 20 mM Tris(hydroxymethyl)aminomethane (Tris)/HCl, pH 7.6 by homogenisation, 
sonification and subsequent centrifugation at 13,000 g. The extracts were further fractionated 
into cytosolic and membrane by ultra-centrifugation at 100,000 g for 1 h. The resulting pellet 
was resupended with equal volumes of 20 mM Tris-HCl, pH 7.6, containing 0.1% -
octylglucopyranoside. Human EDTA plasma was obtained from healthy volunteers. 
Cloning and purification of DP2 
The DP2 gene was cloned into the plasmid pcDNA3.1(+) and COS-7 cells were transiently 
transfected with the plasmid. Expression was examined by Western blot analysis. The cells 
were lysed and the soluble fraction was applied to an affinity resin nickel-nitrilotriacetic acid 
(Ni-NTA) (Pharmacia, Uppsala, Sweden). Active fractions were eluted by 0.3 M imidazole and 
pooled fractions were subsequently applied onto a size exclusion chromatography. The active 
fractions were pooled and used for kinetic investigations. 
Activity and inhibition studies 
Activity was determined with 0.125 mM alanyl-prolyl-7-amido-4-methylcoumarin (Ala-Pro-
AMC) in 40 mM N-2-Hydroxyethylpiperazine-N’-ethane-sulfonic acid (HEPES), pH 7.6 and 
0.25 mM Ala-Pro-AMC in 74 mM NaAcetate, pH 5.5 for DP4-like and DP2 activity, 
respectively. Activity was measured at excitation 380 nm and emission 470 nm with 
microplate reader Fluorostar Optima (BMG LabTech GmbH, Offenburg, Germany). Protein 
concentration was determined by Bradford method, using BSA as standard [12]. The selective 
inhibitors UG 92, UG 93 and DAB were used against DP4, DP8/9 and DP2, respectively. 
P32/98 was a non-selective inhibitor which inhibits all DP4-like enzymes. Inhibitor mix was 
composed of all the selective inhibitors. Except for L-2,4-Diaminobutyrylpiperidinamide 
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(DAB) (Merck Bioscience, Darmstadt, Germany), all inhibitors were synthesized by 
probiodrug.  
MALDI-TOF-Mass Spectrometry 
25 μM NPY (probiodrug AG, Halle, Germany) was incubated with 30 mU of recombinant 
enzyme or tissue extract in absence/presence of selective and non-selective inhibitors. Analysis 
of DP4-like enzymes in tissue extracts was performed in 20 mM Tris/HCl, pH 7.6, while DP2 
was assayed 10 mM 2-(N-Morpholino)-ethanesulfonic acid (MES), pH 5.5. Several aliquots 
were taken between 2 min and 24 h and the reaction was stopped with equal amounts of 0.1 % 
Trifluoroacetic acid (TFA). Afterwards, samples were purified with ZipTip C18 (Millipore 
GmbH, Schalbach, Germany) according to the instructor’s manual, mixed with the matrix 
sinapinic acid at a ratio 1:1, and analysed with MALDI-TOF mass spectrometry (Voyager-DE 
Pro Biospectrometry workstation from Applied Biosystem). For blood analysis, 100 μM NPY 
was applied in the same assay system described above. 
Cell culture  
COS-1 cells (American Type Culture Collection; Rockeville, USA) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal calf serum (BioWest, Essen, Germany) at 
37°C. Plasmid transfection of COS-1 cells was performed with diethylaminoethyl (DEAE) 
dextran [5]. 
Confocal fluorescence microscopy 
Confocal images of living cells were acquired on a Leica TCS SP2 microscope using a 63 
water planachromat lens (Leica Microsystems) essentially as described before [44]. 
Construction of cDNA clones 
DP4 cDNA — mRNA was isolated from the prepared small intestine of F344/Crl(Por/98) rats 
with Qiagen tissue kit. cDNA was synthesized with the First Strand cDNA Synthesis Kit 
(Amersham Pharmacia Biotech, Uppsala, Sweden). PCR reactions were performed with 
primers (MWG-Biotech GmbH) designed after the published mRNA sequence of Rattus 
norvegicus dipeptidyl peptidase 4 [gi:6978772]. For further cloning the chosen sense-primer 
5’-AAAAAAGCTTT GAAGACACCGTGGAAGGTT-3’ introduced a HindIII site (bold) and 
the antisense-primer 5’-AAAGGATCCGAGAGCCTTGCCATGCTA-3’ a BamHI site (bold) 
into the PCR product. rDpp4 was cloned into pEGFP-C1 (Invitrogen/Clontech Laboratories, 
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Inc., Heidelberg, Germany). Constructs were restriction-mapped and sequenced to verify 
correctness of the fragments. 
NPY cDNA — hNPY(-CPON)eGFP-N1 was kindly provided by Richard E. Mains 
(Department of Neuroscience; The University of Connecticut Health Center). GFP was 
replaced by dsRed1 from pcdsRed1-N1 (Invitrogen/Clontech Laboratories, Inc., Heidelberg, 
Germany) by vector digestion with NotI and BamHI (MBI Fermentas, St. Leon-Rot, 
Germany). 
PYY cDNA — rat PYY fragment cloned into pGEM3 encoding a portion of the C-terminal 
extension were kindly provided by Dr. Greeley (University of Texas Medical Branch) [92]. 
The PYY fragment was purified and completed by PCR choosing the following primers: 
thereby the sense-primer 5’-AGAATTCATGGTGGCGGTACGCAGGCCTTGGCCCG 
TTATGGTC-3’ introduced an EcoRI site and the anti-sense primer 5’-TTTGGATCCG 
CCCCACTGGTCCACACCTTC-3’ a BamHI restriction site at the end of the construct. The 
purified PCR product was cloned into the BamHI and EcoRI restriction sites of pcdsRed1-N1. 
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2.4. Results 
Figure 1 clearly depicts that most of the DP4-like activity in brain extracts, determined with the 
chromogenic substrate Ala-Pro-AMC and selective inhibitors, was contributed by DP2, 
followed by DP8/9, whereas only low levels of DP4 could be detected. Interestingly, there 
seemed to be no compensation by the other DP4-like enzymes in DP4 deficient 
F344/Crl(Wiga)SvH-Dpp4m rat substrain (Fig. 1). However, using recombinant human DP2, no 
hydrolysis of NPY could be observed (Fig. 2) in contrast to human recombinant DP4 that 
degraded NPY completely after 30 min (data not shown). Furthermore, MALDI-TOF-mass 
spectrometry of NPY hydrolysis by brain extract from F344/Crl(Por/98) rats in 
presence/absence of selective inhibitors of DP4-like enzymes showed the existence of DP4 and 
DP8/9 as illustrated in Figure 3A-D. On the contrary, NPY hydrolysis of human plasma 
revealed a major contribution by DP4, and a minor one by DP8/9 (Fig. 3E-H). In addition, 
longer incubation of NPY and cytosolic fraction of brain extract confirmed its cleavage to 
NPY2-36 by cytosolic prolyl-aminopeptidase. A dominant fragment of NPY found in all assays 
with brain extracts, was NPY1-30 (Fig. 3 and 4). 
Figures 5A-C show the expression of NPY-dsRed1-N1 and DP4-GFP-C1 in the same 
transfected Cos-1 cell being screened at different wavelengths, thereby measuring emission of 
DP4-GFP-C1 (Fig. 5A) and NPY-dsRed1-N1 (Fig. 5B) fluorescent constructs that are 
transformed to a single image (Fig. 5C) (overlay). The Golgi apparatus, in Figure 5A-C located 
approximately in the center of the picture, is detectable by transported NPY-dsRed1-N1 and 
DP4-GFP-C1 constructs. NPY-dsRed1-N1 containing vesicles leave the trans-Golgi network 
(TGN) and are further transported along cytoskeleton tracks that are clearly indicated in Figure 
5B and 5C. These span over the nucleus, visible below the Golgi apparatus. DP4-GFP-C1 
associated vesicles, are transported through the cytoplasm towards the cell membrane as well, 
where vesicle fusion and integration of DP4-GFP-C1 takes place. Fusion and integration at the 
cell membrane are indicated by non-vesicular appearance of DP4-GFP-C1. Furthermore, 
transport of DP4-GFP-C1 containing vesicles along the cell membrane could be observed. The 
overlay in Figure 5C suggests that DP4-GFP-C1 and NPY-dsRed1-N1 are transported in 
distinct vesicles although sometimes seeming to co-localize in the Golgi apparatus or in the 
cytoplasm due to an overlap or slack flow of different vesicles. Further observations were 
made in Cos-1 cells, transfected with PYY-dsRed1-N1 and DP4-GFP-C1 (data not shown), 
where also no clear evidence for a co-localization of DP4-GFP-C1 and PYY-dsRed1-N1 could 
be demonstrated so far. 
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2.5. Discussion 
In the present paper, the members of the DP4 gene family as well as structural and functional 
homologues are discussed as candidates for N-terminal NPY hydrolysis. While FAP may 
cleave dipeptides from the N-terminus [25], though at a much lower rate, it is highly unlikely 
to hydrolyse NPY endoproteolytically due to its lack of the -Gly-Pro- sequence in -P2-P1-
position [24]. Furthermore, as FAP, is exclusively found in pathogenic tissue [1, 19, 26, 28, 
52, 72] except for serum [55, 56], it can be ruled out as a NPY cleaving enzyme. Although, 
DP2 was shown to be the most dominant DP4-like enzyme in rat brain (Figure 1), it was 
unable to cleave NPY due to its peptide length (Fig. 2) [66, 67]. This is in agreement with 
recent findings of Brandt et al. that investigated the hydrolysis of several potential natural 
substrates by DP2, thereby obtaining no cleavage [13].  
Thus, the remaining DP4-like enzymes potentially cleaving NPY are DP4, DP8 and DP9. 
Using chromogenic substrate and selective inhibitors, higher levels of DP8/DP9 than DP4 
could be clearly demonstrated in the brain as illustrated in Figure 1. Nonetheless, MALDI-
TOF-mass spectrometry showed similar cleavage of NPY by DP4 and DP8/9 respectively, 
confirming the higher catalytic efficiency of DP4 on the one hand [9] and larger representation 
of DP8/9 on the other hand. In addtition, analysis by MALDI-TOF-mass spectrometry could 
also detect NPY2-36 truncation by soluble prolyl aminopeptidase (Fig. 4) [61, 62, 66].  
Preliminary results of enzymatic histochemistry revealed that DP4 is found predominantly in 
the meninges and blood vessels, whereas DP8/9 seemed to be more ubiquitously distributed in 
the brain (data not shown). Conversely, NPY is mainly hydrolyzed by DP4 in human plasma 
and only partially by DP8/9. As there is already strong evidence that serum NPY crosses the 
blood brain border (BBB), one can conclude that peripheral NPY is primarily truncated by 
soluble serum DP4 or during crossing of the BBB by membrane-bound DP4 at the meninges 
and/or blood vessels [51]. Alternatively, NPY from neurons in the brain [6] may most likely be 
cleaved by DP8/9. Thus, neither the histology nor the cytology of NPY cleavage are 
sufficiently understood at this time.  
Peptides of the NPY family are synthesized as large precursor molecules in the endoplasmic 
reticulum. Following post-translational modification, precursor molecules are translocated to 
the Golgi apparatus, sorted in the trans-Golgi network, and guided in vesicles towards the 
secretory pathway. After exocytotic release of NPY-like peptides, their local action relies on 
various circumstances such as their concentration, receptor selectivity and expression of 
Y receptors. However, their half lives and receptor selectivity is strongly modulated by specific 
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peptidases such as the DP4-like enzymes and prolyl-aminopeptidase [61, 62, 66]. Therefore, 
the action of NPY and NPY-like peptides is also influenced by the local distribution and 
concentration of its degrading peptidases either intracellularly or extracellularly [90]. Confocal 
microscopy of COS-7 cells transfected with DP8 or DP9 have shown cytosolic localization 
close to the Golgi apparatus [2, 4]. Analysis by electron microscopy in turn, demonstrated 
granular localization of soluble DP4 in –cells of porcine islets of Langerhans [35, 76]. 
Furthermore, there has been a number of reports on internalization of DP4, partially depending 
on post-translational modification [8, 38, 41, 42, 73, 81, 82].  
Hence, while it is very likely that extracellular peptidases with DP4-like functional homology 
cleave NPY and PYY, there also might be intracellular cleavage resulting in release of N-
terminally truncated peptides. For this reason we performed transfection and confocal 
lasermicroscopy studies in Cos-1 cells and investigated whether DP4 and NPY get into contact 
in the cell and co-localize within vesicles thus enabling a more fine-tuning mechanism via a 
possible cleavage within a vesicle. The possibility of a shared transport path from the trans-
Golgi network in collective transport vesicles or via internalization of DP4 into the cell and 
thus the theoretical ability to modify NPY could not clearly be demonstrated and confirmed by 
the present confocal approach. The techniques used so far do neither exclude nor undoubtedly 
illustrate a co-localization and challenge further studies. 
Although these results provide no direct evidence for an intracellular N-terminal truncation of 
NPY by DP4, in general, an intracellular cleavage cannot be excluded. If NPY is not 
hydrolyzed by DP4 within the cell several other proteases such as DP8 or DP9 remain potential 
candidates for peptide cleavage intra- and extracellular. On the basis of this summary, we can 
conclude that at least up to five enzymatically active peptidases (DP4, DP8, DP9, XPNPEP1, 
XPNPEP2) as shown in Table 1, are potentially involved in NPY cleavage. 
Although DP4 still shows the highest selectivity, each single role of these peptidases should be 
thoroughly investigated in the future. The intracellular and extracellular cleavage of NPY by 
peptidases distinct from DP4 is not only an additional mechanism in the regulation of this 
neuropeptide. It also requires taking the hydrolyzing activities of those peptidases into 
consideration when analyzing DP4 enzyme activities and their associated functions 
downstream in physiology and immunity. Thus, many functions previously ascribed to DP4 
and its inhibition may actually be derived from the activity and inhibition of DP8, DP9, and 
other peptidases that are listed in Table 1. Furthermore, some of the peptidases might be able to 
compensate functions of DP4 after chronic inhibition by selective DP4 inhibitors. 
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Table 1: Structural and functional homologues of NPY cleaving peptidases 
DP4 = dipeptidyl peptidase IV; AAS = amino acid sequence
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Figure 1: Activity and inhibition studies of crude brain extracts, obtained from 
F344/Crl(Por/98) (dark columns) and F344/Crl(Wiga)SvH-Dpp4 (bright columns) rats, 
applying selective inhibitors against DP4-like enzymes. (A) Brain extract assayed with 0.125 
mM Ala-Pro-AMC, pH 7.6 at 37°C; (B) brain extract assayed 0.25 mM Ala-Pro-AMC, pH 5.5 
at 37°C., UG92, DP4 selective; UG93, DP8/DP9 selective; DAB, DP2 selective; mix, UG92 + 
UG93 + DAB; P32/98, non-selective inhibitor. 
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Figure 2: MALDI-TOF-MS analysis of NPY cleavage by recombinant human dipeptidyl 
peptidase 2 (rh-DP 2), showing no cleavage after 6 h incubation at 37°C. 30 mUnits rhDP 2 
were incubated with 25 mM NPY in 10 mM MES buffer, pH 5.5 for 6 h at 37°C. Afterwards, 
the reaction was stopped with 0.1% TFA, samples were purified with ZipTip (Millipore 
GmbH, Germany), mixed with the matrix sinapinic acid at a ratio 1:1 and analysed with 
MALDI-TOF-MS (Voyager-DE Pro Biospectrometry workstation from Applied Biosystems). 
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Figure 3: NPY hydrolysis in crude brain extract from F344/Crl(Por/98) rats or in EDTA-
Plasma determined by MALDI-TOF-MS after 30 min incubation at 37°C in absence or 
presence of different inhibitors. The reaction was stopped with 0.1% TFA, samples were 
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purified with ZipTip (Millipore GmbH, Germany), mixed with the matrix sinapinic acid at a 
ratio 1:1 and analysed with MALDI-TOF-MS (Voyager-DE Pro Biospectrometry workstation 
from Applied Biosystems). (A-D) crude brain extract. (A) without inhibitor; (B) with non-
selective inhibitor P32/98; (C) with DP4 selective inhibitor UG 92; (D) with DP-8/9 selective 
inhibitor UG 93. (E-H) EDTA-plasma. (E) without inhibitor; (F) with non-selective inhibitor 
P32/98; (G) with DP4 selective inhibitor UG 92; (H) with DP8/9 selective inhibitor UG 93. 
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Figure 4: MALDI-TOF MS analysis of NPY hydrolysis by cytosolic brain fraction from 
F344/Ztm rats after 30 min incubation at 37°C. The reaction was stopped with 0.1% TFA, 
samples were purified with ZipTip (Millipore GmbH, Germany), mixed with the matrix 
sinapinic acid at a ratio 1:1 and analysed with MALDI-TOF-MS (Voyager-DE Pro 
Biospectrometry workstation from Applied Biosystems). 
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Figure 5: Confocal analysis of NPY and DP4 in transiently transfected COS-1 cells. Live cell 
image of Cos-1 cell transfected with (A) DP4-GFP-C1 and (B) NPY-dsRed1-N1 48 hours 
post-transfection. (C) Overlay image of DP4-GFP-C1 and NPY-dsRed1-N1. Yellow 
arrowheads indicate DP4-GFP-C1 containing vesicles (A) that do not co-localize with NPY-
dsRed1-N1 (C). Scale bars, 10 μm; n, nucleus; g, Golgi apparatus. 
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Abstract 
Objective. Treatment of diabetes type 2 using chronic pharmacological inhibition of dipeptidyl 
peptidase 4 (DP4) still requires an in-depth analysis of models for chronic DP4 deficiency, 
because adverse reactions induced by some DP4 inhibitors were recently described.  
Research Design and Methods. In the present study, a novel congenic rat model of DP4 
deficiency on a “DP4-high” DA rat genetic background was generated (DA.F344-Dpp4m/SvH 
rats) and comprehensively phenotyped by a combination of different neurobehavioral, 
endocrine, hematological, metabolic, and immune assays.  
Results. Similar to chronic pharmacological inhibition of DP4, DP4 deficient rats exhibited a 
phenotype involving reduced diet-induced body weight gain and improved glucose tolerance 
associated with increased levels of GLP-1 and bound leptin as well as decreased 
aminotransferases and triglycerides. Additionally, DA.F344-Dpp4m/SvH rats showed 
anxiolytic-like and reduced stress-like responses, a phenomenon presently not targeted by DP4 
inhibitors. Whereas all these aspects in the phenotype of this novel model of DP4 deficiency 
may be considered as “beneficial”, several immune alterations such as differential leukocyte 
subset composition (eosinophils, NK cells, B cells) at baseline, blunted NK cell and T cell 
functions, and altered cytokine levels were observed, which may be problematic if appearing 
under conditions of chronic pharmacological inhibition of DP4.  
Conclusions. While this animal model confirms a critical role of DP4 in GLP-1-dependent 
glucose regulation, genetically induced chronic DP4 deficiency apparently also affects stress-
regulatory and immune-regulatory systems, indicating that the use of chronic DP4 inhibitors 
might have the potential to interfere with CNS and immune functions in vivo. 
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3.1. Introduction 
Inhibition of the serine protease dipeptidyl peptidase 4 (DP4) reduces the N-terminal cleavage 
of dipeptides of the insulinotropic peptide-hormone glucagon-like peptide-1 (GLP-1) and 
opens new alternatives for the treatment of diabetes type 2 (1). Within the clinical trials 
performed, these compounds have been demonstrated to be safe and efficacious. However, 
clinical trials including phase III have certain limitations and sometimes, adverse reactions are 
only observed after market introduction. As DP4 is not specific for insulinotropic hormones, 
having also modulating effects on a broad range of other substrates, unwanted effects cannot be 
excluded at this stage. In line with this assumption, recently two compounds were put on hold 
in phase III, in one case for undisclosed toxicity issues and in the other case due to adverse skin 
reactions (www.novartis.com/downloads_new/investors/2006.11.13%20Galvus%20US%20N 
DA%20Review.pdf). Obviously, further preclinical research on potential adverse effects 
caused by chronic inhibition of DP4 is needed. 
We therefore generated a novel congenic DP4 deficient animal model on a defined Dark 
Agouti (DA) rat genetic background with pronounced differences in DP4 activity between 
congenic and wild type animals and studied the effects of this genetically induced DP4 
deficiency in a comprehensive phenotyping approach, following the general rules and 
modifications for rats as previously described (2; 3). For the development of congenic 
DA.F344-Dpp4m/SvH rats, the previously characterized spontaneous point mutation in the 
Dpp4 gene of the F344 rat substrains (F344/DuCrjSvH-Dpp4m and F344/Crl(Wiga)SvH-
Dpp4m) (2; 4-7) was used. This strategy resulted in DP4 deficient animals, being comparable to 
Dpp4tm1Nwa mice (CD26 knockout mice) (8), but providing the advantages of the species Rattus 
norvegicus, being in metabolism, toxicology, and neurobiology more comparable to humans 
(9-12). DP4 is ubiquitously expressed on leukocytes, epithelia and endothelia of most 
vertebrate tissues and is involved in T cell activation and cell adhesion processes as well as in 
the degradation of hormones, chemokines and neuropeptides. Known substrates for DP4 are 
for example substance P (SP), neuropeptide Y (NPY), peptide YY, growth-hormone-releasing-
factor, GLP-1, enterostatin or -casomorphins (13). Relevant substrates in immune reactions 
are for example chemokines (eotaxin, RANTES) (14; 15). These facts strongly suggest that 
new animal models of DP4 deficiency and their comprehensive phenotyping are necessary, as 
DP4 activity modulates numerous psychological and physiological processes affecting 
nervous, endocrine, and immune functions. A priori, no prediction of the resulting effects can 
be made thereof.  
Phenotype of DP4 deficient congenic DA rats: DIABETES, submitted 58 
 
Here, we characterized this new DP4 deficient congenic DA strain and report on a reduced 
body weight gain, both under standard rat chow and high-calorie diet, on improved glucose 
tolerance being associated with increased GLP-1 and bound leptin levels as well as decreased 
aminotransferases and triglycerides. While these findings basically represent the targets of 
pharmacotherapy using DP4 inhibitors, in addition, a reduction in stress-hormone levels 
(ACTH and corticosterone) of the HPA axis associated with anxiolytic-like responses in 
several behavioral assays were observed, which also can be considered beneficial. The 
probably most important findings of this screen were blunted immune functions of natural 
killer (NK) and T cells, altered interleukin-6 (IL-6) and interleukin-10 (IL-10) levels and 
differential leukocyte subset compositions, thus pointing to potential adverse effects as a result 
of a chronic blockade of DP4. We therefore propose to use this mosaic of observations to more 
closely monitor patients, who are presently receiving gliptins (16) as a novel therapy inducing 
chronic DP4 inhibition. 
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3.2 Research Design and Methods 
Animals 
DA/Ztm and DA.F344-Dpp4m/SvH rats were housed and bred at the Central Animal Facility of 
the Hannover Medical School (Ztm) under conditions as described previously (4). All research 
and animal care procedures were approved by the Review Board for the Care of Animal 
Subjects of the district government, Hannover, Germany, and performed according to 
international guidelines for the use of laboratory animals. 
Development of congenic animals 
Development of the congenic strain was started with an initial cross between 
F344/Crl(Wiga)SvH-Dpp4
m
 females, homozygous for the loss-of-function-mutation in the 
Dpp4 gene on RNO3 (4) and a DA/Ztm wild type male rat, to fix the Y chromosome of the DA 
background. Male F1 rats were then backcrossed to DA/Ztm females. Heterozygosity of the 
Dpp4 locus of the resulting N2 males was tested via (a) DP4 expression on T cells using 
Fluorescene activated cell sorting (FACS) analysis of T cell receptor (mAb R73) and DP4 
(mAb Ox61) immunopositive events and via (b) Dpp4 genotyping by means of two gene 
specific microsatellite markers. D3cd26-7 (forward: GGAACTGTTGAATTAGCTCTCTGC; 
reverse: CTCTGGACTGCCATCTCCTACTTC) is localized within Dpp4 and D3cd26-10 
(forward: GCAATCTGGCGCAGAGTAATTAC; reverse: GTCATCTGTCTCCGCTCCCAT) 
is closely linked to Dpp4 on RNO3. The genetic background of N2 DA.F344-Dpp4
m
/SvH 
males, heterozygous for both Dpp4 alleles, was genotyped using 100 polymorphic 
microsatellite markers with an intermarker distance of about 20 cM covering all chromosomes. 
The N2 male with the highest proportion of DA background was selected for the next cross. 
This scheme was used at each generation until N5. A N5 male and a N5 female, homozygous 
for the DA background, were then intermated to produce DA.F344-Dpp4
m
/SvH founders. The 
DP4 deficient congenic DA strain is maintained via brother  sister mating. We used several 
age and sex matched sets of DA.F344-Dpp4
m
/SvH N5F2 rats for the experiments. 
Experimental sets of animals 
To avoid major influences from the high number of different test paradigms applied to the 
animals on the one hand and to confirm certain test results on the other hand, several 
independent sets of age-matched male DA rats – DA/Ztm and DA.F344-Dpp4m/SvH – were 
used for the behavioral studies following rules as previously described (2). 
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Spontaneous feeding behavior, gliadin feeding, high fat diet and body weight gain 
For studying feeding behavior on standard diet (Altromin Standard diet 1320: Altromin GmbH, 
Lage, Germany), the animals were housed either in or kept singly in a cage and the observation 
periods lasted 72 h each (2). For examination of body weight gain under high calorie diet 
animals were fed with a high calorie diet (Altromin, 157p/c1057) and weighed once a week. 
Furthermore, the calorie up-take was determined. For analysis of body weight gain under 
gliadin-rich diet – providing insight into the metabolism with respect to DP4 activity (17) – 
DP4 deficient and wild type DA rats were fed a modified rat diet (modified Altromin Standard 
Diet 1320) for a three week period whereas control rats were fed with non-modified standard 
chow. The modified diet contained gliadin (20%) as single protein source and is high in proline 
compounds. Starting at an age of six weeks, animals were weighed at least once a week 
routinely or as experiments required. 
Oral glucose tolerance test (OGTT) and determination of DP4-like enzymatic activity 
Male DA.F344-Dpp4m/SvH and DA/Ztm animals (21 ± 0.5 weeks of age) were used for these 
experiments being repeated at least three times. Additionally, some animals heterogeneous for 
the mutant Dpp4 gene were included – coded DA.F344-Dpp4m/SvH(-/+). Following an overnight 
fast (12 h) 1 h after the onset of the light phase, animals’ basal blood glucose levels were 
determined (see below). If the glucose concentration was < 7.8 mmol/l (< 140 mg/dl), the 
animals were shortly anesthetized with ether and glucose (2.5 g glucose/kg animal) was orally 
given via a feeding tube. Blood samples (10 μl) were collected from the tail vein of conscious 
rats at 30, 60, 90, and 120 min following the oral glucose load and the glucose level was 
measured by a glucometer (Bayer, Leverkusen, Germany) using criteria as previously 
described (4). For determination of DP4 enzymatic activity, EDTA-plasma samples from 
experimentally naïve animals were kept at -80°C until being assayed using a microplate based 
chromogenic assay. The release of 4-nitroaniline (pNA) from the substrate glycyl-prolyl-4-
nitroaniline (Gly-Pro-pNA) was monitored at 405 nm and 37°C using the PowerWaveXS 
Universal Microplate Spectrophotometer (BioTek Instruments, Bad Friedrichshall, Germany). 
The assay is selective for DP4-like activities, however, due to the alkaline pH it neglects the 
contribution by dipeptidyl peptidase 2. One unit is defined as the amount enzyme necessary to 
hydrolyze 1 μmol substrate (18). 
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Insulin, GLP-1, bound/free leptin 
Insulin levels were determined using an Insulin-RIA-Kit (Biotrend, Chemikalien GmbH, Köln) 
according to the manufacturers instructions. Plasma samples were taken 15, 30, 45 min after 
oral glucose challenge under the condition described in the glucose tolerance test, respectively. 
For determination of active GLP-1(7-36) via ELISA kit (Linco; Glucagon Like Peptide-1 
(Active)) EDTA-plasma samples were conditioned with 10-5 M of isoleucyl-thiazolidide and 
handled according to the manufacturer’s instructions. Plasma samples were taken 30 min after 
oral glucose challenge. Bound leptin was measured using a specific radioimmunoassay (RIA) 
developed at the Department of Gastroenterology, Hepatology and Endocrinology, Hannover 
Medical School (19), while total leptin was measured using a RIA from Linco (Linco St. 
Charles, Missouri, USA). 
Clinical chemistry 
The auto-analyzer ADVIA 1650 (Siemens Medical Solutions Diagnostics GmbH, formerly: 
Bayer Vital GmbH), installed and validated at Clinical Pathology, Institute of Toxicology, 
Merck KGaA, Germany was used to determine various electrolytes and enzymes in 300-500 μl 
serum per animal derived from retro orbital blood samples. The data were generated according 
to standardized procedures and valid methods including internal controls (Duotrol Normal Lot 
No 5066, and Duotrol Abnormal Lot No 5077, BIOMED) resulting in scientifically reliable 
data. 
Histology of pancreas, liver, and hypothalamus 
Pancreas and liver samples were collected from either paraformaldehyde (PFA) fixed animals 
or HOPE fixation of samples was used. HOPE fixiation was conducted as recently described 
(20). Samples were transferred either into paraffin (HOPE) or kept frozen in cryoprotectant 
(PFA), sectioned (liver: 3-4 μm; pancreas: 6-7 μm; brain: 15 μm) and stained. Detection of 
free leptin (Ob-A20; Santa Cruz Biotechnology Inc., Santa Cruz, CA; 1:500 overnight at 4°C) 
in liver was conducted as previously described (21). Pancreatic beta cells were detected by 
insulin immunostaining with a polyclonal guinea-pig antibody (Insulin A 565, dil. 1:4000; 
DAKO, Hamburg, Germany). For double labeling of hypothalamus, animals were perfused 
using 4% PFA, brains removed, postfixed (12 h), cryoprotected (sucrose solution) and then cut 
coronally in a cryostat at 40 μm thickness. Free floating sections were processed for 
immunohistochemistry using a combination of the avidin-biotin-peroxidase complex (ABC) 
and the alkaline phosphatase-anti-alkaline phosphatase (APAAP) methods (7) by incubating 
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overnight at 4°C with rabbit anti-human/ratNPY polyclonal antibody (1:4000; affinity purified; 
Biotrend, Köln, Germany; # NA1233, Batch Z02052) and anti-rat DP4/CD26 monoclonal 
antibody (mAb) (clone 5E8, 1:500, Cell Science Inc., Canton, MA 02021). The dilutions of the 
antisera were made with Tris HCL containing 0.3% Triton X-100, and 5% normal goat serum. 
For ABC staining, the sections were first incubated for 1 h at RT with the biotinylated 
secondary anti-rabbit antibody (1:200 in 5% normal goat serum and 0.3% Triton X-100) and 
subsequently exposed to ABC complex (1:100; ABC Kit elite, Vector Labs, Burlingam, CA). 
After visualization of the APAAP reaction by Fast Blue reaction product (22), the reaction 
product of the ABC stain was visualized with 0.1% DAB. Control sections were included, in 
which one or both primary antibodies were omitted. Sections from the level of the 
hypothalamus, arcuate nucleus, and median eminence were evaluated using microscope. 
General health and neurological examination  
Gross abnormalities that would interfere with further behavioral testing such as general health, 
sensory abilities, and neurological reflexes were controlled and compared between the DA 
congenic and DA wild type rats as described previously for mice and rats (2; 3). 
Determination of motor functions (Accelerod test) and circadian activity (Home cage 
activity) 
An Ugo Basile accelerating rotarod (model 7750) for rats, supplied by Technical & Scientific 
Equipment GmbH (TSE GmbH), Bad Homburg, Germany, was used and training as well as 
experiments were conducted as previously described (11). For monitoring home cage activity, 
an infrared sensor controlled recording system (model No. E61-01/08; Coulbourn Instruments, 
Allentown, PA, USA) was used as previously described (23). This test is based on infrared 
detection of number and time of movements and it is useful to screen for differences in 
circadian rhythm. Activity peaks are defined as “small” and “large movements”, indicating 
when activity/movements took place within a duration being shorter or longer than 3 s, 
respectively. As a representative readout, the “time spent in large movements per time interval” 
was chosen as an indicator for circadian activity pattern. 
Evaluation of stress-induced hyperthermia, anxiety and exploratory behavior 
For determination of stress-induced hyperthermia, body temperature was repeatedly 
determined before and after a brief stressor (transport stress) according to Kask and colleagues 
(24). The elevated plus maze (EPM), social interaction (SI), and the holeboard assay were used 
to evaluate anxiety-like and exploratory-like behaviors, respectively. An EPM apparatus (TSE 
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GmbH) (23), a SI (24), and a self-made holeboard (23) were validated and used as previously 
described. 
Two-way active avoidance shuttle box learning and test of prepulse inhibition (PPI) 
Shuttle box conditioning was used as a test of associative learning and was conducted using a 
TSE Shuttle box system (TSE-Systems GmbH) following the protocol as previously described 
(11). PPI of a startle response is the phenomenon, in which a weak prepulse suppresses the 
response to a startling stimulus. Deficits in prepulse inhibition are common in schizophrenic 
patients. An automated startle system (TSE GmbH) was used as previously described (2).  
Determination of corticosterone, ACTH, IL-6 and IL-10 levels 
Corticosterone (AA-13F1, Lot 37170; IDS, Boldon, UK) levels were detected in EDTA-
plasma samples via RIA (obtained via IBL, Hamburg, Germany). Detection was conducted in 
duplicates according to the manufacturer’s guidelines. For corticosterone, the calculated 
sensitivity was 0.39 ng/ml and the intra- and interassay coefficients of variation were 5 and 
9%, respectively. ACTH, IL-6, and IL-10 were measured by means of ELISA using previously 
described standard techniques for hormones and cytokines according to Straub et al. (25). 
Quantification of NK cell cytotoxicity in spleens of DA substrains 
NK cytotoxicity was measured in classical 51Cr-release assays using splenocytes and YAC-1 
target cells, which were derived from standard cell culture conditions, as previously described 
(22). The specific cytotoxicity was calculated by means of the following formula: 
[(experimental release) – (spontaneous release)] / [(maximal release) – (spontaneous release)] 
 100. In addition, the percentage of CD3-CD161+ NK cells in each spleen was determined by 
FACS analysis as previously described (7; 26) and lytic units (LU) were calculated according 
to the method of Bryant et al. (27). Since mononuclear cells were used as effector cells, LU 
were further mathematically adjusted to NK cell numbers present in the respective assays by 
forming the quotient LU/NK cells (%). 
Haematology 
Two validated Bayer Diagnostics automated hematology systems (ADVIA 120) including 
species-specific software settings were used. EDTA blood samples (200 μl) were collected by 
retrobulbar venipuncture and analyzed using standard methods and controls. 
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FACS analysis 
Leukocytes were counted using a Coulter counter and then further processed for flow 
cytometry using three colour stainings as previously described (26) with the following details 
being modified. Briefly, about 1106 cells per well were incubated with mouse anti-rat mAb 
for 20 min at 4°C using the following marker for granulocytes (FSC/SSC/mAb HIS48), 
monocytes (mAb ED9/mAb W3/25), B lymphocytes (mAb OX12), CD4+ T cells and CD8+ T 
cells (mAb R73/mAb W3/25/mAb OX8), and NKbright cells (mAb 10/78). Dendritic cells were 
defined using the mAbs OX62 and OX6. All antibodies were purchased from serotec 
(Germany). 
T cell proliferation assay 
Rat peripheral blood mononuclear cells (PBMC) were isolated from fresh, arterial EDTA blood 
via centrifugation on Ficoll gradient (Ficoll Paque TMPlus, Amersham, Sweden). PBMC 
number and viability was determined by cell counting using trypan blue staining. Cells were 
washed and the proliferation assays were conducted in 96 well flat-bottom plates. Therefore, 
2105 cells per well were cultured in the presence of 0.2 μg  TCR antibody (plate bound). 
Cells stimulated with 1 μg Concanavalin A served as positive controls. After 5 days of 
incubation the proliferation rate was quantified by BrdU incorporation and detected with a 
specific colorimetric BrdU Cell proliferation ELISA (Roche Molecular Biochemicals, 
Mannheim, Germany) according to the manufacturers instructions. BrdU incorporation was 
measured using an ELISA reader (PowerWaveXS Universal Microplate Spectrophotometer; 
BioTek Instruments, Inc., Winooski, U.S.A.) at 370 nm and 492 nm as reference wavelengths. 
Results were expressed as absorbance rates (A370nm-A492nm). 
Statistical analysis 
Analysis of the various behavioral and physiological data was assessed either by applying 
repeated measures analysis of variance (ANOVA) on successive measurements or by one-way 
ANOVA. In repeated measures ANOVA the nominal independent variable “substrain” was 
used as the “between factors” and different continuous response variables within successive 
measurements were used as the “within-factors” (e.g. body weight over time). In case of 
significant differences in regard to the “between factor” or significant interactions of 
“between” and “within-factors”, this was followed by one-way ANOVAs (factor: “substrain”); 
split by the dimension of the continuous response variable (e.g. split by the different time-
points of body weight determination). One-way ANOVAs were followed by the Fisher-PLSD-
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test for post hoc comparison to evaluate pair wise differences among levels of main effects. 
The “between-subject effects” from ANOVAs are presented within the text in the results 
section by providing the degrees of freedom (for the “between factor” and for the “within 
subject error”), F-values, and p-values, while in figures and tables the p-values of the results 
obtained by the corresponding post hoc tests are provided, if appropriate. Differences were 
regarded as statistically significant if p was below .05. The number of animals per substrain (n) 
was at least 10. Presenting the degrees of freedom indicates exceptions from this. Significant 
post hoc effects versus the control animals of the DA/Ztm substrain are indicated by asterisks 
(*p < .05; **p < .01; ***p < .001). All data are presented as means ± standard error of the 
mean (SEM). 
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3.3. Results 
DP4 deficiency reduces body weight, protects from high-fat diet induced obesity, 
improves glucose tolerance, increases GLP-1 and leptin, and lowers aminotransferases as 
well as triglycerides. Reduction of DP4 enzymatic activity became a widely accepted target 
that has been proven beneficial in the treatment of type 2 diabetes. Consequently, we studied 
parameters related to glucose metabolisms and body weight homeostasis in the DA.F344-
Dpp4m/SvH rats. Figures 1 and 2 illustrate these findings and clearly demonstrate various 
levels of beneficial effects in a genetically induced status of DP4 deficiency. While the genetic 
background of male DA wild type rats is characterized by high levels of DP4-like activity, DP4 
deficient DA.F344-Dpp4m/SvH rats exhibited negligible low, and heterozygous DA.F344-
Dpp4m/SvH(+/-) rats intermediate DP4-like activity (F(2, 86) = 876.5, p < 0.0001; Fig. 1A). 
Similar findings were observed in female animals ((-/-) 1.88±0.1 [mU/ml]; (+/+): 36.1±1.2 
[mU/ml]; (+/-) 15.3±0.9 [mU/ml]). In support of DP4 being the key regulator in glucose 
homeostasis, testing glucose tolerance in the OGTT revealed a significantly improved response 
towards glucose load in DP4 deficient rats (F(2, 20) = 10.04, p = 0.001; Fig. 1B), being 
comparable to pharmacologically induced DP4 deficiency in mice (28; 29). Interestingly, 
heterozygous animals exhibited an intermediate phenotype, clearly illustrating an association 
between “gene dosis”, DP4 activity, and glucose tolerance. 
Furthermore, these findings were associated with significantly elevated levels of active GLP-
1(7-36) (F(1, 6) = 8.8, p = 0.02; Fig. 1C) in DA.F344-Dpp4m/SvH rats being detectable at 30 
min after oral glucose challenge. In addition, a trend toward elevated insulin levels (mean over 
three measurements at 15, 30, and 45 min: 0.4 ng/ml in DA.F344-Dpp4m/SvH vs. 0.3 ng/ml in 
wild type; Fig. 1D) was found. Similar to Dpp4tm1Nwa mice, interestingly, ß-islet size was 
reduced in the DA.F344-Dpp4m/SvH rats (Fig. 1E), potentially suggesting an increase of 
insulin storage. 
Screening of body weight gain (Fig. 1F) revealed a significantly reduced increase in DP4 
deficient animals (F(1,19) = 12.1, p < 0.001), which parallels gain in body weight of wild type 
animals until about one year of age, when these differences became more apparent. Also, high-
calorie diet induced weight-gain was significantly blunted in animals being about one year of 
age (Fig. 1F; small insert), although calorie up-take did not differ. Apart from this, no other 
obvious differences in general health, reflexes and sensory abilities were observed at any time. 
Furthermore, no significant differences for food or water consumption were observed at the 
age of 3, 6, and 9 months (data not shown). 
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Beneficial effects of DP4 deficiency in glucose metabolism (30; 31) may also be reflected in 
lipid metabolism (1,13). Actually, our findings provide evidences that DP4 deficiency 
facilitates leptin signaling (32; 33). This notion is reflected by histological evaluation of free 
leptin in liver tissue that illustrates increased levels in wild type animals (Fig. 2A) and by high 
levels of bound leptin in DA.F344-Dpp4m/SvH rats (F(1, 6) = 5.6, p = 0.04; Fig. 2B). Levels of 
total leptin were not significantly altered in plasma (data not shown). As leptin is expressed 
predominantly by adipocytes, which represents to some extend the total mass of fat in the 
body, we also measured triglyceride levels (TG) and found a reduction in DA.F344-
Dpp4m/SvH rats (F(1, 17) = 20.09, p < 0.001). This is probably also sufficient to explain the 
observed statistical significant but albeit minor decreases in amino transferases (alanine 
aminotransferases (ALAT), (F(1, 17) = 15.3, p = 0.001), aspartate aminotransferases (ASAT), 
(F(1, 17) = 7.08, p = 0.01)) and alkaline phosphatase (AP), (F(1, 17) = 8, p = 0.01) (Fig. 2C). 
Table 1 illustrates that no other differences were found in parameters such as electrolytes 
except for minor increases of urea and inorganic phosphate in DA.F344-Dpp4m/SvH animals. 
Thus, the DP4 deficient congenic rats also exhibit improved liver metabolism, which further 
hints to beneficial metabolic situation in DP4 deficient animals. 
Having these findings on glucose and lipid metabolism along with corresponding GLP-1/leptin 
signaling in mind, it remained open to investigate the potential interaction of DP4 with proteins 
(e.g. gliadin, and proline-rich proteins) and protein metabolism especially in the intestine, as 
DP4 is highly expressed in the ileum and jejunum. In particular, the role of DP4 in the small 
intestine and the kidney is dipeptide re-absorption after cleavage of proline containing peptides 
and oligopeptides (17; 34; 35). This gives rise of problems that might occur as a possible 
consequence of chronic treatment using long acting DP4 inhibitors in diabetes type 2. Notably, 
it has already been shown that gliadin-based diet being rich of proline (17; 36) causes 
malabsorption of such proteins. Consequently, wild type and DA.F344-Dpp4m/SvH rats 
received a modified gliadin-rich and otherwise non-modified diet. As expected, results (Fig. 
2D) of three factorial ANOVA for repeated measures revealed full interaction of the between-
subject factors "genotype", "diet composition", and the within subject-factor "delta body 
weight" in DP4 deficient rats showing a significant body weight loss (F(4, 80) = 7.1, p < 
0.0001), and illustrating an impaired ability of protein utilization. Overall, these findings 
already confirmed that this new rat model of DP4 deficiency exhibit many if not all of the key 
features being targeted by DP4 inhibitor treatment. Nonetheless, as many of the substrates of 
DP4 (NPY, SP, endomorphin, etc) play a significant role in the central nervous system (CNS) 
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and peripheral nervous system (PNS), we then characterized the behavioral phenotype and the 
stress-response of these animals in-depth. 
Multi-tired behavioral analysis of DP4 deficient DA.F344-Dpp4m/SvH rats reveals a stress 
protective and anxiolytic-like phenotype. Multi-tired behavioral phenotyping compromises 
repeated tests for various behavioral domains being additionally complemented by tests of 
neurological reflexes and sensory abilities. Every behavioral domain (e.g. motorfunction, 
anxiety, cognition, etc.) should be screened repeatedly and confirmed by at least two different 
tests challenging similar adaptational responses (2; 3). In the case of genetically and 
pharmacologically induced DP4 deficiency, we have already shown that DP4 deficient F344 
rats exhibit a phenotype of reduced stress-responsiveness and anxiety (2; 5). In the current 
study, we characterized a new animal model of DP4 deficiency (congenic DA.F344-
Dpp4m/SvH rats) that - in contrast to the previously used DP4 deficient F344 rat substrains - 
reveals a homogeneous genetic background and that exhibits higher DP4-enzymatic activity 
levels in wild type DA/Ztm rats. A priori, this difference should also cause a more pronounced 
anxiolytic and stress-protective like phenotype. 
Results show that under home-cage conditions there are no differences in diurnal activity (Fig. 
3A; p > 0.05 n.s.). Furthermore, testing of motor functions on the rotarod and of startle-
response along with prepulse inhibition (PPI) (tested e.g. in repeated accelerod and PPI tests, 
data not shown), cognitive performance in associative learning task of the two way active 
avoidance shuttle box paradigm (Fig. 3B; p > 0.05 n.s.), as well as pain perception under 
habituated conditions (data not shown) revealed no differences between wild type DA/Ztm and 
DA.F344-Dpp4m/SvH rats. In contrast, DP4 deficient congenic animals responded to all tests 
related to stress and anxiety in a very different way. Namely, stress-induced rise of body 
temperature (stress-induced hyperthermia, Fig. 3C) was significantly blunted (F(1, 18) = 8.5; p 
= 0.009), illustrating a reduced response to stress, probably mediated by decreased SNS 
activity (24). In support of this, reduced levels of ACTH (Fig. 3D) and corticosterone (Fig. 3E) 
were detected in plasma from DP4 deficient rats, thus underlining that the endocrine stress 
response corresponded to the behavioral phenotype. Furthermore, analysis of the social 
interaction test of anxiety revealed an increased total social interaction time for DP4 deficient 
DA.F344-Dpp4m/SvH rats (F(1,23) = 25.5, p < 0.0001; Fig. 3F) being indicative for anxiolysis. 
Similarly, using the EPM test, DA.F344-Dpp4m/SvH rats show higher values for percent of 
open arm entries (F(1,14) = 4.5, p = 0.04; Fig. 3G) and for percent of time spent in open arms 
(F(1,14) = 4.9, p = 0.04; data not shown). Concerning motor activity in this test (number of 
closed and total arm entries), no significant differences were found (data not shown). 
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Investigation of explorative behavior and locomotor activity in the holeboard test revealed that 
DP4 deficient DA.F344-Dpp4m/SvH rats made significantly more head dips than DA/Ztm 
animals (F(1,16) = 6.9, p = 0.02; Fig. 3H). Additionally, DA.F344-Dpp4m/SvH rats spent 
significantly more time in the center of the board (F(1,16) = 5.3, p = 0.03; data not shown). 
Again, no differences in motor activity - measured by the distance covered by entering 
different squares – were found (data not shown). Double immunohistochemistry of DP4 (blue 
APAAP staining) and NPY (dark brown vesicular precipitate) in the hypothalamus (section at 
the level of bregma -3.12 mm according to Paxinos and Watson, 2007; Fig. 3I) illustrates that 
at least NPY in the arcuate hypothalamic nucleus (ARC) as a anxiolytic- and stress-protective-
like acting substrate of DP4, is expressed in the close vicinity of the corresponding DP4 
enzyme. The latter is expressed in blood vessels of the MEE (blue staining, arrow heads) of 
DA wild type (Fig. 3I) but not in DA.F344-Dpp4m/SvH rats (Fig. 3I, insert in upper right 
corner; lack of blue staining, arrows).  
Differential immune cell distribution, blunted immune cell function and altered cytokine 
levels as consequence of DP4 deficiency in DA.F344SvHDpp4 rats. To complete the 
comprehensive phenotyping, we screened for immunological parameters that might be affected 
by DP4 deficiency (at experimentally naïve conditions or after in vitro stimulation of T and 
NK cells) and that possibly might indicate where adverse reactions of chronic DP4 inhibitor 
treatment may occur.  
As DP4 deficiency as well as inhibitor treatment have been shown to affect hematopoiesis and 
the behavior of bone marrow stem cells, e.g. via modulation of the chemokine, stromal cell 
derived factor-1 (SDF-1/CXCL12) (37), we first screened hematological parameters. The 
hemogram showed significantly reduced absolute cell numbers in DA.F344-Dpp4m/SvH rats 
for lymphocytes (F(1, 18) = 5.5, p = 0.03) and eosinophils (F(1, 18) = 5.02, p = 0.04) (Fig. 
4A), which may demonstrate specific changes at local chemokine action at e.g. the level of 
bone marrow and thymus. In the case of eosinophils for example, we have recently shown 
regulatory effects of DP4 for the recruitment of eosinophils in vivo via prolonged action of the 
CCR3 ligand CCL11/eotaxin (Forssmann et al., 2007, unpublished), which may also explain 
reduced levels of eosinophils at baseline in this study. In addition, determination of blood 
leukocyte subsets by FACS analysis (Fig. 4B) revealed a significant increase of NK cells (F(1, 
7) =11.06, p = 0.007), B cells (F(1, 7) = 6.2, p = 0.03) and CD5 positive B1-like cells (F(1, 7) 
= 8.6, p = 0.03) in DP4 deficient rats. In previous studies we have shown that especially these 
leukocyte subpopulations are mobilized by NPY infusions (38), suggesting that apart from 
altered local chemokine metabolism also DP4 mediated N-terminal truncation of the 
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noradrenergic co-transmitter NPY at the local level of sympathetic innervated immune organs 
such as the spleen might be involved in this phenomenon. A similar mechanism may also lead 
to a NPY potentiated noradrenalin-mediated increase of the splenic IL-6 outflow (25) (Fig. 
4G). Table 2 demonstrates that granulocytes, monocytes, dendritic cells and CD4+ and CD8+ T 
cells were not significantly affected. Surprisingly, similar to the blood pool, also the percentage 
of NK cells in the spleen was significantly increased in DA.F344-Dpp4m/SvH rats – a finding 
which also has been observed in Dpp4tm1Nwa mice (39) – suggesting that an overall increase of 
NK cells in these animals is evident. The determination of lytic units (LU20/10
7, Fig. 4C) 
revealed that in comparison to DA/Ztm rats, an increased number of effector cells is needed in 
DA.F344-Dpp4m/SvH rats to lyse 20% of the target cells. Due to the above mentioned higher 
percentage of NK cells in the spleen of DA.F344-Dpp4m/SvH rats (F(1, 6) =24.7; p = 0.003; 
Fig. 3D) the ratio of LU to percent of NK cells reveals a significantly reduced cytotoxicity per 
NK cell of DP4 deficient DA rats (F(1, 6) =6.1, p < 0.05; Fig. 4E). Thus, the absolute capacity 
of a single NK cell to lyse tumor targets is reduced in DA.F344-Dpp4m/SvH rats. 
Besides differences in NK cell numbers and cytotoxicity, also a significantly blunted T cell 
proliferative response was observed. In comparison to NK cells, a priori it was more likely to 
find differences in this lymphocyte subpopulation, as T cell functions might be affected at very 
different regulatory levels including but not limited to antigen presenting cell (APC)-T cell 
interaction, T cell costimulation, and memory function (40), TGF-ß signaling (41; 42), T 
memory cell to regulatory T cell (Treg) switch, or chemokine metabolisms (14; 15). Here we 
found in DP4 deficient animals a five-fold reduced proliferation rate upon stimulation with 
anti--TCR mab (F(1, 5) =32.9, p = 0.001 Fig. 4F). Furthermore, IL-6 levels are significantly 
reduced in DA.F344-Dpp4m/SvH rats (F(1, 7) = 7.6, p = 0.02), whereas no significant 
differences were found in the determination of IL-10 (Fig. 4G). 
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3.4. Discussion 
The recent introduction of sitagliptin (Januvia(R)) to the market as well as the fact that 
vildagliptin (Galvus(R)) has put on hold by the FDA both challenge an in-depth analysis of 
potential effects of chronic DP4-inhibition, other than improved glucose homeostasis (16). A 
priori, all studies investigating a status of long lasting DP4 deficiency in experimental animals, 
either achieved pharmacologically or genetically, are complementary to each other and 
relevant at this point. Here, we decided to take the advantage of the genetically induced chronic 
DP4 deficiency in the rat, and generated a novel DP4 deficient congenic model in order to 
facilitate an in-depth characterization of potential effects aside from the enteroinsular axis and 
to make use of the advantages of the species Rattus norvegicus e.g. with regard to behavioral 
alterations. Consequently, a comprehensive phenotyping approach was conducted, which not 
only was focused on endocrine but also on neurobehavioral and immune alterations as all these 
might result in side effects during chronic treatment of diabetes. 
In the current study, we report that a comprehensive phenotyping of neurobehavioral, 
endocrine, hematological, metabolic, and immune parameters in DA.F344-Dpp4m/SvH rats 
reveals DP4 dependent changes on at least three levels: (a) beneficial effects on the 
enteroinsular axis, glucose homeostasis, and body weight regulation not only via GLP-1 but 
also via leptin and liver dependent processes, (b) potent anxiolytic-like and stress-protective 
like effects, and (c) considerable changes in immune cell distribution and NK cell and T cell 
functions. While the metabolic effects largely cover the therapeutic targets of current drug 
development, the behavioral changes may represent a novel field of application for DP4 
inhibitors, whereas the immune changes probably point to an area, where most likely unwanted 
effects might appear. Thus, the current results highly suggest tight supervision of 
immunological parameters in patients currently receiving DP4 inhibitors for the treatment of 
diabetes to detect any potential side-effects. 
More specifically, the improved metabolic status of this novel DA.F344-Dpp4m/SvH rat model 
largely reflects findings in Dpp4tm1Nwa mice (8; 31), DP4 deficient F344 rats (2; 4) and in rats 
and mice receiving chronic DP4 inhibitor treatment (28; 29; 43), strongly supporting this 
concept for lowering blood glucose levels. In addition, our study reveals that the DP4 deficient 
phenotype of DA rats is characterized by reduced body weight gain as well as resistance to 
high calorie diet induced obesity suggesting that inhibition of DP4 may also be used for 
treatment of obesity without manifest diabetes type 2. Lower body weight may be a result from 
increased levels of bound leptin, but this is in contrast to an unaltered food intake, which was 
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observed in our study as well as in DP4 deficient F344 rats (2) and KO mice (31), which 
together hints to effects mediated either via higher metabolic rates or malabsorption. In this 
study, no differences in home cage activity were observed, thus, excluding that differential 
physical activity levels are responsible for the lower body weight in free feeding DA.F344-
Dpp4m/SvH rats. Although no differences in baseline body temperature were found in DA rats, 
leptin is reported to increase energy expenditure (44; 45) which might have contributed to 
differences in body weight. Interestingly, malabsortion of gliadin leads to a reduction of body 
weight (17) (Fig. 2D). Although, the latter represents an artificial model being unlikely to be 
observed in patients receiving DP4 inhibitors, the consequences resulting from reduced DP4 
activity are non-negligible. Thus, malabsorption of other proline-rich diets as well as breast-
feeding of children by mothers receiving DP4 inhibitors in conjunction with malabsorption of 
-casomorphin, may both lead to loss of body weight or failure to thrive. In the latter case, a 
connection between DP4 activity and -casomorphin in atopic dermatitis and potentially other 
immune disorders was suggested (46).  
While the changes in body weight regulation and glucose homeostasis mentioned above, 
strongly support current drug developmental strategies, importantly, the stress-protective and 
anxiolytic-like phenotype observed in the present study as well as in our previous reports in 
DP4 deficient F344 rats (2; 5) may represent a novel target for drug development. We 
demonstrate here that DA.F344-Dpp4m/SvH rats additionally show increased exploratory 
behaviors and reduced stress-like as well as anxiolytic-like behavioral responses that were also 
reflected on the endocrine level. While more frequent visits on open arms of the EPM and of 
social encounters in novel environment represent classical behavioral indicators of reduced 
anxiety in rodents (3) reduced corticosterone, ACTH, and stress-induced hyperthermia indicate 
that also the hypothalamic-pituitary-adrenal axis as well as the sympathetic response to stress 
are blunted. Our leading hypothesis is that DP4 deficiency in mutant F344 rats (2; 5) as well as 
congenic DA.F344-Dpp4m/SvH rats prolongs the half-life of endogenous NPY(1-36), which binds 
with high affinity the NPY Y1 receptor. This receptor is mainly responsible for NPY mediated 
anxiolysis and stress-protection (47; 48). N-terminal cleavage of NPY by DP4, leading to 
NPY(3-36) results in a much lower Y1 receptor affinity by this truncated peptide, thereby 
abrogating anxiolytic-like action of NPY. To this end, the interaction of NPY and DP4 takes 
place at the level of the hypothalamus, where high expression of NPY and DP4 in blood 
vessels is apparent (Fig. 3I) but other limbic areas and Y1 receptor expression sites may be 
involved as well. Last but not least, this concept of DP4 mediated modulation of NPY Y1 
receptor mediated may also account for the peripheral action of NPY in the PNS and immune 
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system as for example suggested by the increased levels of IL-6 (25). Concerning the CNS 
effects, presently, it remains open whether current DP4 inhibitors on the market will cross the 
blood-brain-barrier at a significant level thereby allowing interaction of CNS neuropeptide-
substrates and DP4. Furthermore, little distinctive anxiolytic-like and stress-protective effects 
may have not been discovered in phase 2 and phase 3 studies, even when considering that such 
effects only become apparent after stress. 
Whereas the “beneficial” metabolic as well as the appreciable anxiolytic/stress-protective-like 
actions, induced by DP4 deficiency, together represent a fascinating perspective for the 
application of DP4 inhibitors, probably, problems will appear in the area of immune regulation. 
Thus, already the present rat model exhibits several immune alterations at baseline or non-
challenged conditions, which consist in differential leukocyte subset composition (eosinophils, 
NK cells, B cells), blunted NK cell and T cell functions, and altered cytokine levels.  The most 
likely mechanisms for this plethora of effects probably have to be searched in different 
regulatory loops affected by DP4 deficiency. These are changes in T cell co-stimulation (40) 
and in chemokine metabolism (15), obviously also affecting hematopoetic stem cells (49). 
With regard to an altered chemokine metabolism it should be noted that at least several CCR3 
ligands (eotaxin, RANTES), as well as the CXCR4 ligand CXCL12 (SDF-1; stromal derived 
factor 1) and all CXCR3 ligands all represent substrates of DP4. While in healthy, non-
challenged conditions, i.e. phase 1 studies or genetically deficient animal models, modulatory 
effects induced by a prolonged half-life of these mediators may only be weakly expressed (i.e. 
alterations in blood and spleen leukocyte pools, as observed for eosinophils, B cells, and NK 
cells in the present study), at infectious or allergic states these processes might become crucial 
in patients (6; 50). As such conditions are not tested during phase 3 studies, their relevance for 
human patients remains open and probably will become overt during the introduction of DP4 
inhibitor into clinics. Similarly, a modulated CD26 dependent T cell co-stimulation via 
caveolin-1 mediated, APC-dependent upregulation of CD86, the principle ligand of CD28, or 
CD26-mediated co-stimulation via intracellular signaling via Carma-1 (40) may represent 
another problem, which becomes relevant after introduction of CD26-inhibitors into clinics. 
Namely, the response to recall-antigens on T cell as well as B cell levels may be blunted (40). 
Last but not least, since also tumor cell adhesion (7) and – as shown here – NK cell 
distribution/function are modulated by DP4, it cannot be excluded at this stage that also NK 
dependent responses such as defenses against viral infections and tumors are modulated under 
chronic DP4 inhibition. 
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In conclusion, the present comprehensive characterization of DA.F344-Dpp4m/SvH rats reveals 
a phenotype being composed of at least three major dimensions: (1) improvements in glucose 
and lipid metabolism being associated with a caveat of malabsorption of proline-rich diets, (2) 
surprising and very promising anxiolytic/stress-protective like effects, which need to be 
explored with regard to their clinical applicability, and (3) critical immune changes at baseline 
as well as after in vitro challenge, which hint to this area as the major impact regarding 
potential side-effects. Based on this plethora of findings in our novel model of DP4 deficiency, 
more specific DP4 inhibitors (i.e. organ specific) and more specific pharmacodynamics (i.e. 
short lasting compounds), appear to be necessary. 
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3.7. Tables and figures 
Table 1: Clinical chemistry in DP4 deficient DA rats 
Parameter in serum DA/Ztm DA.F344-Dpp4m/SvH 
Inorganic posphate [mmol/l] 1.2 ± 0.0 1.4 ± 0.1* 
Urea [mmol/l] 4.9 ± 0.1 5.7 ± 0.2** 
Natrium [mmol/l] 142.1 ± 0.3 141.5 ± 1.3 
Potassium [mmol/l] 3.5 ± 0.1 3.6 ± 0.2 
Calcium [mmol/l] 2.5 ± 0.0 2.5 ± 0.0 
Chloride [mmol/l] 100.8 ± 0.6 100.4 ± 1.0 
Glucose [mmol/l] 9.2 ± 0.3 9.04 ± 0.4 
Creatine [μmol/l] 37.2 ± 1.3 35.7 ± 1.4 
Total bilirubin [μmol/l] 1.8 ± 0.1 1.8 ± 0.1 
Cholesterol [mmol/l] 2.6 ± 0.1 2.5 ± 0.1 
Total protein [g/l] 66.0 ± 0.5 65.03 ± 0.9 
Albumin [g/l] 40.3 ± 0.4 39.8 ± 0.5 
 
 
Phenotype of DP4 deficient congenic DA rats: DIABETES, submitted 82 
 
Table 2: Leukocyte subsets in DP4 deficient DA rats 
 DA/Ztm DA.F344Dpp4m/SvH 
Leukocytes [n x 103] 7170 ± 411 7284 ± 179 
% of abs. leukocytes 
Mononuclear cells 86.22 ± 1.2 86.76 ± 1.3 
Granulocytes 13.78 ± 1.3 13.24 ± 1.3 
IgMpos B cells 18.98 ± 1.1 21.96 ± 1.1 
IgMpos CD5pos B cells 0.96 ± 0.2 1.20 ± 0.2 
DC (MHC-IIpos E integrinepos) 0.64 ± 0.1 0.62 ± 0.1 
Monocytes (CD4pos CD172apos) 6.68 ± 0.5 7.20 ± 0.5 
NK (CD161pos) 3.26 ± 0.2 4.28 ± 0.3 
T cells (/ TCRpos) 46.82 ± 3.1 43.86 ± 4.9 
CD4pos T cells 35.27 ± 1.9 33.25 ± 3.4 
CD8pos T cells 11.74 ± 0.6 11.04 ± 0.5 
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Figure 1: Glucose homeostasis and body weight related parameters in DP4 deficient 
(DP4neg) DA.F344-Dpp4m/SvH and wild type (DP4pos) DA/Ztm rats: DP4-like activity in 
DA/Ztm (+/+), DA.F344-Dpp4m/SvH (-/-) and additionally heterozygous DA animals (+/-) (A). 
Glucose tolerance 30-120 min following oral glucose challenge (OGC; indicated by arrow) in 
DA/Ztm (+/+), DA.F344-Dpp4m/SvH (-/-) as well as DA congenics that are heterozygous for 
DP4 (+/-). Significant effects, indicated by asterisks, only refer to DA.F344-Dpp4m/SvH vs 
DA/Ztm wildtype (B). GLP-1(7-36) levelsin DP4pos and DP4neg rats 30 min post oral glucose 
challenge (C). Insulin levels in DP4pos and DP4neg rats 15, 30, and 45 min post oral glucose 
challenge (D). Insulin staining of pancreatic islets in DP4pos and DP4neg rats. A representative of 
the maximal islets size shown in the beta cell area is illustrated, scale bar = 100 μm (E). Body 
weight of the different substrains between 6 and 90 weeks of age; bottom: body weight gain 
under high calorie diet (HCD), BL, baseline, w1-w4, week 1-4 of HCD (F). Data represent 
means ± SEM. Significant group difference derived from post-hoc analysis are indicated by 
asterisks (*p < .05; **p < .0 1; ***p < .0 01 vs DA/Ztm wild type). 
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Figure 2: Metabolic changes, and clinical chemistry in DP4 deficient (DP4neg) DA.F344-
Dpp4m/SvH and wild type (DP4pos) DA/Ztm rats: Immunohistological detection of free leptin 
in hepatocytes in DP4pos and DP4neg rats, scale bar = 100 μm. Strong immunoreactivity is 
represented by intensity of cytosolic red colour (A). Bound leptin levelsDP4pos and DP4neg rats 
(B). Clinical chemistry findings on alanine aminotransferase (ALAT), aspartate 
aminotransferase (ASAT) and alkaline phosphatase (AP) [U/l], and triglycerides (TG) [mmol/l] 
in serum samples (C). Impact of gliadin-rich, modified food on weight gain. Animals were fed 
with modified and non-modified food over a three-week period (D). Data represent means ± 
SEM. Significant group difference derived from post-hoc analysis are indicated by asterisks 
(*p < .05; **p < .0 1; ***p < .0 01 vs DA/Ztm wild type). 
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Fig. 3: Stress-protective and anxiolytic-like phenotype in DP4 deficient congenic DA rats: 
Diurnal home cage activity pattern. Activity of DA/Ztm (DP4pos) and DA.F344-Dpp4m/SvH 
(DP4neg) rats was recorded over a period of three days. The diagram represents activity during a 
22 h recording interval and displays the time spent in large movements (movements longer 
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than 3 s) being collapsed into sums 15 min total activity (A). Associative learning across 8 
days in the two-way active avoidance shuttle box paradigm (B). Stress-induced hyperthermia. 
The rectal temperature was determined in non-stressed, experimentally naïve rats (t0) as well as 
at two time points after a brief stressor (tStr1 and tStr2) (C). in DP4
pos and DP4neg rats (D). in 
DP4pos and DP4neg rats (E). Time spent in active social interaction as parameter for anxiety-like 
behaviors in the social interaction test; pairs of non-familiar either DP4pos or DP4neg rats were 
exposed to an open field 1h after onset of dark phase for 10 min and sum of time of their active 
“sociopositive” behaviors was recorded (F). Anxiety-like behaviors in the EPM test are 
reflected by the percentage of open arm entries. Animals were tested in the elevated plus maze 
1 h after onset of dark phase (G). Exploratory behavior in the holeboard test. The number of 
head dips was recorded during a 10 min session (H). Hypothalamic co-expression of DP4 
(blue) and NPY (brown vesicular staining) expression sites (I). Arrow heads indicate blue 
staining for DP4 in blood vessels the eminentia mediana, external layer, in DP4pos rats, while 
no such immunoreactivity was seen in DP4neg rats (arrows in the small insert, upper right of I); 
VMH = ventromedial hypothalamic nucleus, ArcD = arcuate hypothalamic nucleus, dorsal 
part, ArcM = arcuate hypothalamic nucleus, medial part, ArcL = arcuate hypothalamic nucleus, 
lateral part, V3 = 3rd ventricle, MEE = medial eminence, external layer, MEI = medial 
eminence, internal layer (I). Data represent means ± SEM. Significant effects are indicated by 
asterisks (*p < .05; ***p < .0 01 vs DA/Ztm wild type). 
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Figure 4: Immunological differences in DA congenics lacking DP4 activity (DA.F344-
Dpp4m/SvH) and in DA wild type (DA/Ztm) rats: Differential blood cell distribution  of 
DP4pos and DP4neg rats; white blood cells (WBC), red blood cells (RBC), platelets (PLT) (A, 
left and right). Differential leukocyte subsets determined via FACS (B, left and right). Specific 
cytotoxity (spec. cytotox.) against and YAC-1 target cells (C). Splenic NK cells in % (D). LU 
per 1 % NK cells (E). T cell proliferation was assayed in PBMCs from DP4pos and DP4neg rats 
(F). Cytokine levels of IL-6 and IL-10 (G). Data represent means ± SEM. Significant effects 
made are indicated by asterisks (*p < .05; **p < .0 1 vs DA/Ztm wild type). 
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Abstract 
Dipeptidyl-peptidase IV (DP4) is involved in several physiological functions, some of which 
are dependent on DP4’s ability to N-terminally truncate dipeptides of the neurotransmitter 
neuropeptide Y (NPY1-36). The remaining C-terminal fragment NPY3-36 has a relatively lower 
affinity for the NPY receptor subtype Y1. The Y1 receptor is involved in stress-protective, 
anxiolytic-like and analgetic-like effects of NPY. In a genetic study, we tested stress-induced 
analgesia SIA in two spontaneously mutated DP4 deficient F344 rat substrains and in a DP4 
deficient congenic DA rat strain. We also investigated whether intracerebroventricular (i.c.v.) 
administration of NPY (vehicle, 0.2, or 1.0 nmol) or the DP4 inhibitor isoleucyl-thiazolidide 
(Ile-Thia) (vehicle, 0.5, or 5.0 nmol) modulates the pain threshold in DP4 deficient F344 rat 
substrains compared to wild type-like F344 control animals. All three animal models for DP4 
deficiency exhibited a blunted stress-dependent increase of the nociceptive threshold in the 
non-habituated hot plate paradigm illustrating a process of reduced SIA. This difference was 
lost after habituation to the hot plate paradigm. Centrally administered NPY decreased pain 
sensitivity of DP4 deficient F344 substrains in the non-habituated and habituated hot plate, 
whereas pharmacological inhibition of DP4 resulted in an increased pain threshold in wild 
type-like animals, which was similar to DP4 deficient animals. Immunohistology of the 
hypothalamus revealed expression of DP4 in the close vicinity of NPY positive neurons of the 
paraventricular nucleus. The study demonstrates that stress-induced analgesia depends on DP4 
expression and suggests a mechanism via N-terminal truncation of NPY, subsequently 
resulting in reduced Y1 receptor-like tone and associate loss of stress-protective/anxiolytic-like 
effects. 
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4.1. Introduction 
The enzyme and binding protein dipeptidyl peptidase 4 (DP4; CD26) belongs to the class of 
membrane-associated peptidases (De Meester et al., 1999). Due to its unique ability to liberate 
Xaa-Pro and Xaa-Ala dipeptides from the N-terminus of regulatory peptides, substrates for 
DP4 include neuropeptides such as neuropeptide Y (NPY), endomorphin, and substance P (De 
Meester et al., 2000; Hildebrandt et al., 2000; Mentlein, 1999). These have been shown to exert 
analgetic-like effects, with NPY undergoing the highest relative cleavage rate and thus being a 
highly affine substrate (Bjelke et al., 2006; Mentlein, 1999). 
We have previously investigated the role of loss of DP4 enzymatic activity on behavioural and 
physiological processes in two mutant F344 rat models for DP4 deficiency (i.e. 
F344/DuCrjSvH-Dpp4m and F344/Crl(Wiga)SvH-Dpp4m) – for details see Karl et al. (Karl et 
al., 2003a; Karl et al., 2003b; Karl et al., 2003c). In a systematical behavioural and 
physiological characterization, we observed reduced anxiety-like behaviours and an associated 
reduction in stress-induced analgesia in both DP4 deficient F344 rat substrains compared to 
wild type-like F344 rats (Karl et al., 2003c). Namely, we observed that under non-habituated 
conditions of the hot-plate assays, both DP4 deficient substrains exhibited a reduced threshold 
in showing aversive responses. This phenomenon was lost after habituation to the potentially 
stressful context of the hot plate assay (Karl et al., 2003c), thus being strongly suggestive for a 
status of blunted stress-induced analgesia under a condition of genetic DP4 deficiency and for 
a stress-protective effect of this deficiency.  
NPY affects anxiety and nociception (Kask et al., 2002; Naveilhan et al., 2001; Wettstein et al., 
1995) and an involvement of the Y1 receptor subtype has been documented. Importantly, the 
described anxiolytic-like phenotype of the mutant substrains – giving rise to their reduced 
stress-induced analgesia (Wolf et al., 2007) – is very likely associated with differential 
degradation and utilization of NPY, strongly suggesting that a more potent NPY Y1 receptor-
like tone in these rats causes this behavioural effect (Karl et al., 2003b). However, the direct 
effect of NPY on nociceptive responses remains controversial: some studies describe an 
analgetic effect of exogenous NPY (Hua et al., 1991; Merlo Pich et al., 1990) and an 
involvement of the Y1 receptor (Gibbs et al., 2004; Gibbs et al., 2006), others discuss a 
nociception-increasing effect (Broqua et al., 1996; von Horsten et al., 1998) or did not find any 
effect of NPY on pain threshold (Heilig et al., 1993; Jolicoeur et al., 1991).  
As NPY represents one of the best substrates for DP4 (Bjelke et al., 2006), we considered here 
increased levels of this endogenous mediator first as being responsible for the stress-protective-
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like phenotype of DP4 deficient F344 rats during their response to novelty (i.e. the non-
habituated hot plate assay) and for the associated modulation of central pain processing (i.e. the 
blunted stress-induced analgesia).  
In a first step we wanted to exclude any impact of reported variations in the genetic 
background of the F344 substrains (Karl et al., 2003a) on the nociceptive phenotype. Thus, we 
generated a DP4 deficient congenic strain on the Dark Agouti (DA) rat genetic background. 
For this, we transferred the mutant Dpp4 allele of the F344/Crl(Wiga)SvH-Dpp4m substrain 
onto a DA/Ztm background and tested these animals for SIA in the hot plate paradigm. In a 
second step, we characterized the phenomenon of SIA in mutant F344 substrains 
(F344/DuCrjSvH-Dpp4m, F344/Crl(Wiga)SvH-Dpp4m). We also investigated, whether identical 
doses of intracerebroventricular (i.c.v.) administered NPY in control and mutant F344 rats 
would lead to a differential nociceptive response in the hot plate design. Finally, we analysed 
whether pharmacological inhibition of DP4 (i.c.v. treatment with isoleucyl-thiazolidide) has a 
similar effect on pain sensitivity of wild type-like control F344 rats as caused by the genetic 
depletion of DP4 in the two mutant F344 substrains. This series of experiments was completed 
by immunohistological studies seeking for expression of NPY and DP4 in brain areas involved 
in the modulation of stress. 
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4.2. Materials and methods 
Animals 
F344 substrains obtained in 1998 from breeding colonies of Charles River Laboratories (Crl) in 
Sulzfeld, Germany (Thompson et al., 1991), and Atsugi, Japan (Tiruppathi et al., 1993; 
Watanabe et al., 1987), almost completely lack DP4-like activity and protein expression. This 
DP4 deficiency cannot be detected in wild type-like F344 rats from Crl breeding colonies in 
Portage, USA or Hannover (Ztm), Germany (Karl et al., 2003a). In our previous reports (Karl 
et al., 2003a; Karl et al., 2003b; Karl et al., 2003c) F344 rat substrains derived from breeding 
colonies of CR in Atsugi, Japan were named F344/DuCrj(DPPIV-), animals from breeding 
colonies in Sulzfeld, Germany, F344/Crl(Ger/DPPIV-), and wild type-like rats obtained from 
colonies in Portage, USA, F344/Crl(Por). Since we have further inbred these mutant lines for 
more than 10 generations, and since some of them are not commercially available from CR 
anymore, we code them nowadays F344/DuCrjSvH-Dpp4m for the Japanese and 
F344/Crl(Wiga)SvH-Dpp4m for the German DP4 deficient line as well as F344/Crl(USA) for 
the wild type-like control rats, respectively.  
All adult, male test animals (F344/DuCrjSvH-Dpp4m, F344/Crl(Wiga)SvH-Dpp4m, 
F344/Crl(USA), DA.F344-Dpp4m/SvH and DA/Ztm) were housed and bred at the Central 
Animal Facility of the Medical School Hannover. Animals were maintained in a separated 
minimal barrier sustained facility and kept in macrolon type III cages with standard bedding 
(Altromin GmbH, Lage, Germany). Food (Altromin Standard diet 1320: Altromin GmbH, 
Lage, Germany) and water were available ad libitum. Environmental temperature was 
automatically regulated at 21 ± 1°C and relative humidity was 60% with an air change rate of 
15 times per hour. The animal rooms were operated with a positive pressure of 0.6 Pa. Rats 
were maintained under a 12:12 h light regime. They underwent routine cage maintenance once 
a week. Routine microbiologic monitoring according to FELASA recommendations 
(Rehbinder et al., 2000) did not reveal any evidence of infection with common murine 
pathogens except for Pasteurella pneumotropica and Staphylococcus aureus. All research and 
animal care procedures were approved by the Review Board for the Care of Animal Subjects of 
the district government, Hannover, Germany, and performed according to international 
guidelines for the use of laboratory animals. 
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Generation of congenic DP4 deficient DA strain 
Development of the congenic strain was started with an initial cross between 
F344/Crl(Wiga)SvH-Dpp4m females, bearing the loss-of-function-mutation in the Dpp4 gene 
and male DA/Ztm rats. The DA rat strain was selected as a recipient strain due to its high 
endogenous DP4-like enzymatic activity, ensuring that congenics on DA background exhibit 
pronounced differences compared to the wild type-like strain (Karl et al., 2003c). Male F1 rats 
were then backcrossed to DA females. Heterozygosity of the Dpp4 locus of N2 males was 
tested by analysing DP4 expression on T-cells using FACS analysis of T cell receptor (mAb 
R73) and DP4 (mAb OX61) immunopositive events and by genotyping the Dpp4 using two 
informative microsatellite markers (D3cd26-7 and D3cd26-7). 
The genetic background of heterozygous N2 DA.F344/Crl(Wiga)SvH-Dpp4m males were 
genotyped using informative microsatellite markers with an intermarker distance of about 
20 cM spanning the whole genome/chromosomes. The N2 male with the highest proportion of 
DA background was selected for the next cross. This scheme was used at each generation until 
N5. A N5 male and a N5 female, homozygous for the DA background, were then mated to 
produce DA.F344-Dpp4m/SvH founders. The DP4 deficient congenic DA strain is maintained 
through brother x sister mating. We used DA.F344-Dpp4m/SvH N5F2 rats for the experiments 
(DA/Ztm rats used as controls).  
Determination of DP4-like enzymatic activity 
All test animals were characterized for their DP4-like enzymatic activity as described 
previously (Karl et al., 2003a). For determination of plasma activity of F344 and congenic rats 
a microplate based chromogenic assay was used. EDTA-plasma samples were kept at –80°C 
until use. DP4 enzyme activity of the different rat substrains was determined by monitoring the 
release of 7-amino-4-methylcoumarin (AMC) from the substrate Gly-Pro-AMC at 360/480 nm 
(Ex/Em) and 30°C using the Novostar fluorescence microplate reader (BMG, Offenburg, 
Germany). The assay consists of 20 μl plasma sample, 100 μl H2O and 100 μl HEPES buffer 
pH 7.6 and 50 μl Gly-Pro-AMC. Activity was calculated from the linear slope using a factor of 
3.116x10-4 μmol/l calculated from an AMC standard curve and the sample dilution. One unit is 
defined as the enzyme activity, which cleaves 1 μmol Gly-Pro-AMC per minute. The assay is 
selective for DP4-like activities, however, due to the alkaline pH it neglects the contribution by 
dipeptidyl peptidase 2. Importantly, the chromophores are not released by other proline-
specific peptidases, such as prolidase, prolyl endopeptidase or aminopeptidase P. 
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Surgery (I.c.v. cannulation) 
For surgery F344 rats were anaesthetized with an intramuscular (i.m.) mix of ketamine 
hydrochloride (0.1 ml/100 g body weight; Albrecht, Aulendorf, Germany) and dormitor 
(0.01 ml/100 g body weight; Pfizer GmbH, Karlsruhe, Germany). The i.c.v. cannulation 
technique was identical to a previous report (von Horsten et al., 1998). After placement of the 
rat in a Kopf stereotactic apparatus (Model 900: David Kopf Instruments, Tujunga, USA), the 
incisor bar was adjusted on position zero and the ear bars were adjusted to equal positions so 
that the rat’s head was fixed in the apparatus. The eyes were protected against drying with eye-
salve (Bepanthen Augen- und Nasensalbe: Hoffmann-La Roche AG, Grenzach-Wyhlen, 
Germany). The skull was exposed by a midline incision, the periost was removed, the bone 
surface was dried, and the position of the bregma was identified. Three stainless steel anchor 
screws (Breitfeld & Schliekert, Karben, Germany) were secured to the skull and a stainless 
steel guide cannula (Plastics one, Roanoke, USA) was implanted in the right lateral ventricle 
and cemented in place with dental cement (Durelon Maxicap: Espe Dental AG, Seefeld, 
Germany). The coordinates for the lateral ventricle were 0.7 mm caudal and 1.6 mm lateral to 
the bregma, with the guide cannula (Plastics one) extending 3.4 mm ventral to the skull 
surface.  
Flow of small amounts of 0.9% saline (Braun Melsungen AG, Melsungen, Germany) through 
the protracted injection (internal) cannula (Plastics one, Roanoke, Germany) was used to verify 
that the guide cannula was positioned just above the ventricular system. The guide cannula was 
fitted with a dummy cannula (Plastics one, Roanoke, USA) of the same length to prevent 
leakage of cerebrospinal fluid. Animals were housed individually after surgery. The anatomical 
position of the cannulation was verified by post mortem i.c.v. dye application (Berlin blue) and 
inspection of third ventricular staining in randomly chosen rats. The animals of the three F344 
substrains F344/DuCrjSvH-Dpp4m, F344/Crl(Wiga)SvH-Dpp4m and F344/Crl(USA) were 
operated at the age of 95 (± 5) days. After a recovery phase of 10 days we commenced 
observation of the animals’ behaviour in the hot plate task. 
Drug dosages and i.c.v. application procedure 
A stock solution of human/rat NPY (2 mol; Polypeptide GmbH, Wolfenbüttel, Germany) was 
adjusted under sterile conditions to final concentrations (0.2 nmol/5 μl and 1.0 nmol/5 μl) 
using 0.9% saline. The final concentrations were made 24 h before testing. Animals were 
habituated to experimental i.c.v. injections daily for seven days prior to the start of the first 
experiment. For i.c.v. administration, animals were taken out of the home cage and the dummy 
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cannula was replaced by the internal cannula. Peptide or 0.9% saline were injected i.c.v. at a 
volume of 5 μl over 20 s through the internal cannula extending 4.4 mm ventral to the skull 
surface. The internal cannula was attached to a microsyringe (Hamilton Bonaduz AG, 
Bonaduz, Switzerland) with approximately 30 cm of polyethylene tubing (Plastics one, 
Roanoke, USA), which allowed the animal to move freely during the i.c.v. injection. Before 
the rat was placed back into the home cage the dummy cannula was re-attached. Experiments 
started 15 min after administration. During the habituation phase the handling procedure was 
exactly the same but no compound was administered. Two different doses of NPY were used 
for this study and a 3 (substrain)  3 (treatment) experimental design was set up. Thus, F344 
rats of each substrain were subdivided into three treatment groups each, which were treated 
with either 0.9% saline (vehicle: 0.0 nmol/5 μl), 0.2 nmol/5 μl or 1.0 nmol/5 μl NPY. Seven 
days later animals were treated either with 0.9% saline (vehicle: 0.0 nmol/5 μl), 0.5 nmol/5 μl 
or 5.0 nmol/5 μl of the DP4 inhibitor isoleucyl-thiazolidide (Ile-Thia: Probiodrug AG, Halle, 
Germany).  
Nociception (Hot plate) 
A 30 x 30 cm hot plate analgesia meter (Columbus Instruments, Columbus, USA) was used for 
this experiment, which was carried out during the light phase of the light cycle. The experiment 
was performed as previously described (Karl et al., 2003c). The rat was placed on the surface 
of the apparatus, which was maintained at 52.5°C. The latency to respond (lick or raise a 
hindpaw) was recorded. To prevent any damage to the animals, rats were removed from the hot 
plate if they did not respond within 20 s (Naveilhan et al., 2001; von Horsten et al., 1998). 
F344/DuCrjSvH-Dpp4m, F344/Crl(Wiga)SvH-Dpp4m and F344/Crl(USA) rats’ nociceptive 
response was tested 15 min after treatment with different dosages of either NPY (or saline) or 
Ile-Thia (or saline - seven days after NPY treatment). The recently generated DA.F344-
Dpp4m/SvH rats and their DA/Ztm controls were tested twice for nociception: 1) non-
habituated (day 1) and 2) seven days later after being habituated to the test apparatus 
(habituation on the inactivated hot plate for 1 min per day on days two, four, and six).  
Double immunoflourescence of hypothalamic immunoreactivity for NPY and DP4 
Animals were perfused as previously described (Kask et al., 2001). 30 mm coronal 
cryosections of the rat hypothalamus that were defined by the anatomical atlas were cut on a 
cryostat (Paxinos and Watson, 1989). All sections were collected in 0.1 M PBS and processed 
after the free-floating method. After initial washing steps, sections were placed in a pre-
incubation solution containing 10 % NDS, 0.3% Triton X-100 in 0.1 M PBS (1 h, RT). 
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Sections were incubated with the anti-rat DPPIV/CD26 monoclonal antibody (clone 5E8, 
1:500, Cell Science Inc., Canton, MA 02021) for 48 h at 40C on a horizontal shaker. 
Subsequently, sections were washed and incubated with an anti-mouse-Cyanin 2 conjugated 
antibody (1:1500, diluted in 0.1M PBS) for 45 min. Finally, sections were washed extensively 
in 0.1 M PBS and further processing were performed in the dark. For double 
immunoflourescence staining, sections were incubated at 4°C with rabbit anti-human/ratNPY 
polyclonal antibody (1:200; affinity purified; Biotrend, Köln, Germany; # NA1233, Batch 
Z02052). Following subsequent washes, sections were labeled using Cyanin-3-coupled anti-
rabbit antibody (1:1500, 2 hr, RT), diluted in 0.1 N PBS. In some cases, DAPI nuclear staining 
was applied according to standard procedures. Control sections were included, in which one or 
both primary antibodies were omitted. All sections were analyzed using a Nikon light 
microscope (Eclipse 80i; Nikon, Tokyo, Japan), Nikon objectives (Plan Apo, VC 2, NA = 
1.0; Plan Apo VC 40, NA = 1.1), motorized specimen stage for automatic sampling 
(Märzhäuser, Wetzlar, Germany), electronic microcator (Heidenhain, Traunreut, Germany), a 
dedicated Nikon HiSN fluorescence system, a Nikon cooled DS-5Mc camera, and imaging 
software (Stereo Investigator, MicroBrightField, Williston, VT). 
Statistical analysis 
The behavioural data were analysed using a two-way analysis of variance (ANOVA; factor: 
"strain"  "treatment") and/or one-way ANOVA (factor: "strain" or "treatment" - split by the 
corresponding factor) followed by the Fisher-PLSD-test for posthoc comparison, if 
appropriate. Differences were regarded as statistically significant if p < .05. Results present the 
degrees of freedom, F-values, and p-values of the ANOVAs, while in figures and tables the p-
values of the corresponding posthoc tests (Fisher-PLSD-test) are provided. The number of 
animals per strain/treatment group was n = 8, with exceptions indicated by the degrees of 
freedom. Significant posthoc effects for the factor "strain" versus the control animals of the 
F344/Crl(USA) substrain or the DA/Ztm strain are indicated by asterisks (*p < .05; **p < .01; 
***p < .001). All data are presented as means ± standard error of the mean (SEM). 
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4.3. Results  
DP4-like enzymatic activity 
One-way ANOVA of the DP4-like activity of the congenic DA.F344-Dpp4m/SvH rats revealed 
a significantly decreased level of activity for the congenic rats compared to the wild type-like 
DA/Ztm control strain [F(1;7) = 416.4; p < .0001; Fig. 1A]. Screening of the different F344 
substrains confirmed a near complete lack of enzymatic DP4-like activity for F344/DuCrjSvH-
Dpp4m and F344/Crl(Wiga)SvH-Dpp4m animals and a wild type-like pattern of DP4-like 
activity for the F344/Crl(USA) control substrain [F(2;61) = 400.4; p < .0001; Fig. 1B].  
Nociception (Hot plate) 
Non-habituated, vehicle-treated DP4 deficient F344 rats of both substrains exhibited a 
significantly increased nociception (two-way ANOVA for latency to lick/raise a hindpaw – 
factor "strain": F(2;55) = 10.1; p < .0001 – one-way ANOVA for "vehicle": F(2;19) = 6.9; p < 
.01; Fig. 2A) compared to control animals (F344/Crl(USA)). Importantly, i.c.v. NPY increased 
dose-dependently the pain threshold of mutant but not wild type-like F344 rats so that initially 
observed nociceptive differences disappeared (one-way ANOVA for "0.2 nmol": F(2;189) = 
4.2; p < .05; for "1.0 nmol": non significant; Fig. 2A). Due to the reported lack of response to 
NPY treatment in F344 control rats, two-way ANOVA revealed only a trend (two-way 
ANOVA: F(2;55) = 2.3; p = .08) for i.c.v. NPY to increase the pain threshold. 
Analysing the effects of DP4 inhibition on nociception in these F344 substrains confirmed 
once more the decreased pain threshold for vehicle-treated mutant F344 substrains "at 
baseline" (two-way ANOVA; factor "strain": F(2;44) = 4.9; p = .01; one-way ANOVA for 
"vehicle": F(2;18) = 3.6; p < .05; Fig. 2B). I.c.v. injections of 0.5 nmol or 5.0 nmol Ile-Thia 
attenuated the differences in nociception between the different substrains by increasing the 
pain sensitivity of the control F344/Crl(USA) substrain but not DP4 deficient rats (Fig. 2B). 
Transferring the genetics for DP4 deficiency onto a DA background (DA.F344-Dpp4m/SvH 
rats) resulted in a phenotype similar to mutant F344 substrains. The newly generated congenic 
DP4 deficient rats exhibited increased pain sensitivity in the non-habituated hot plate task 
(one-way ANOVA: F (1; 15) = 22.7; p < .001; Fig. 3). Similarly, the significant decrease in the 
latency to raise or lick a hindpaw disappeared after habituation  (one-way ANOVA: F (1; 15) 
= 1.6; non significant; Fig. 3). 
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Histological findings 
Figure 4 illustrates representative photomicrographs at the level of the third ventricle (3V) and 
the paraventricular hypothalamic nucleus (PVN) in lower (upper row) and higher 
magnification (lower row) of DP4 (A, D; green flourescence) and NPY (B, E; red 
flourescence) in wild type-like F344 rat brain (F344/Crl(USA)). Panels C and F represent 
overlays of A and B as well as D and E, respectively.  
In general, strong DP4-like immunoreactivity (ir) was found at meninges, blood vessels, and 
the circumventricular organs such as the median eminence (data not shown). No evidence for 
neuronal expression of DP4-like protein was found in wild type-like and mutant brains. NPYir 
was present at multiple areas of the CNS including substantia gelatinosa of the dorsal horn of 
the spinal cord, several hypothalamic nuclei such as the paraventricular nucleus and the arcuate 
nucleus. Consistently, no obvious difference in the distribution pattern of NPYir fibres and cell 
bodies were found between the various F344 substrains. Although there was an overlap in the 
distribution pattern of DP4ir and NPYir within the before-mentioned brain areas, under a 
higher magnification, no clear co-localization of DP4ir and NPYir was observed at a cellular 
level (Fig. 4C and F). However, NPY positive neurons were found in close proximity to DP4-
positive structures such as blood vessels or in the circumventricular organs (i.e. the median 
eminence on the level of the arcuate nucleus). Furthermore, DP4-like ir was found in the 
subependymal layer of the third ventricle close to the PVN of the hypothalamus (arrows). In 
addition, processes of NPYir neurons were closely associated with blood vessels. 
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4. 4. Discussion 
We report here that mutant F344 as well as congenic DA substrains – all lacking endogenous 
DP4 enzymatic activity – show increased pain perception, interpreted as reduced stress-
induced analgesia, in a non-habituated hot plate paradigm. I.c.v. administration of NPY 
reverses this increase in pain sensitivity in the DP4 deficient F344 substrains dose-
dependently. In the same line, central inhibition of DP4 by the DP4 inhibitor Ile-Thia resulted 
in reduced stress-induced analgesia in wild type-like control F344 rats.  
These effects show parallels to DP4 deficient congenic DA rats and to the previously reported 
mutant F344 substrains in the non-habituated hot plate test. Consequently, we conclude that 
central DP4-like enzymatic activity exerts an important modulatory effect on central pain 
processing. Furthermore, the data suggest that the DP4 substrate NPY is implicated in this 
process. In line with this, we hypothesize the involvement of NPY in nociception via two 
different levels/pathways: a) NPY’s influence on stress-induced analgesia by mediating the 
amplitude of stress via the antinociceptive and stress-reducing action of its Y1 receptor - with 
the endogenous NPY tonus being under control of DP4, and b) the antinociceptive effect of 
i.c.v. NPY, which produces analgesia/antinociception by activation of its Y1 receptors. 
So far, neither the interaction of NPY and DP4 nor the potential of NPY in reducing stress and 
thus controlling the dimension of stress-induced analgesia have been considered in pain 
perception. In two recent publications we described an anxiolytic-like and nociceptive 
phenotype for DP4 deficient F344/DuCrjSvH-Dpp4m and F344/Crl(Wiga)SvH-Dpp4m rats 
(Karl et al., 2003b; Karl et al., 2003c). The reduced behavioural stress response of mutant F344 
rats is very likely based on differential NPY catabolism leading to an increased Y1 receptor-
like tone. The Y1 receptor is the main mediator of NPY’s well-described anxiolytic-like effects 
(Heilig, 2004; Kask et al., 2001). We also showed that the nociceptive phenotype of DP4 
deficient F344 rats was associated with a reduced stress protection in these animals. This 
implies an impact of stress-induced analgesia (Kelley, 1986; Kelly, 1982) and endogenous 
NPY release (Heilig, 2004) on this nociceptive phenotype (for details see: Karl et al., 2003b).  
Importantly, a similar increase in nociception was found for the newly generated congenic rats 
(DA.F344-Dpp4m/SvH) that are also characterized by reduced stress and anxiolysis. Thus, we 
have excluded influences of the genetic background of the F344 substrains on their phenotype 
and confirmed that in fact differential expression and function of DP4 modulates pain 
perception in the non-habituated hot plate task.  
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In early experiments of acute stress (Akil et al., 1976; Madden et al., 1977), stress-induced 
analgesia was reversed by habituation to an experimental setting. In addition, stress-induced 
analgesia was accompanied by an increase in brain endogenous opioids (Madden et al., 1977). 
This phenomenon could be antagonized by non-specific centrally acting opioid antagonists and 
was found to be partially reversible by the opioid antagonist naloxone (Akil et al., 1976). 
Moreover, pain or any kind of stress – psychological, infectious or traumatic – activates 
corticotropin-releasing hormone (CRH) neurons (Chrousos and Gold, 1992; Crofford et al., 1994). 
Furthermore, stress-induced activation of the hypothalamic-pituitary axis has been shown to 
produce analgesia (Amit and Galina, 1986). 
As NPY is a key mediator of stress-protective effects (Heilig, 2004; Kask et al., 2001), which 
could also be observed in the DP4 deficient rat substrains, the neuropeptide may very likely 
modulate stress-induced analgesia. In DP4 deficient rats, NPY may reduce stress levels via an 
increased activation of the Y1 receptor. This increased Y1 receptor-like tone would alter 
baseline arousal of these substrains in the non-habituated hot plate test. Attenuated stress levels 
would lead to a reduced release of opioids. In addition, it has to be mentioned that pronounced 
reduction of endogenous DP4 activity also affects DP4 substrate metabolism other than NPY 
and some of its substrates are powerful modulators of pain perception as well. 
DP4 inhibition via i.c.v. Ile-Thia had no effect on hot plate latencies in mutant F344 substrains. 
However, control rats exhibited increased pain sensitivity after pharmacological DP4 
inhibition, which was identical to the nociceptive phenotype of our genetic animal model for 
DP4 deficiency. Similar effects were found in another study for wild type-like but not DP4 
deficient knockout mice (Guieu et al., 2006). 
Histological findings indicate clear expression of DP4 immunoreactivity at sites of the blood-
brain-barrier [i.e. blood vessels, circumventricular organs (CVOs) and meninges] but little or 
no evidence for DP4 expression/activity at distinct brain areas or even neurons. A close 
association of both proteins was found at the CVOs and ventricle walls at the level of the 
hypothalamus. The expression of DP4 at CVOs offers interesting possibilities for DP4-
mediated alteration of endogenous stress modulating peptides such as NPY, the neuropeptide 
pituitary adenylate cyclase-activating polypeptide, and SP. As all of these peptides represent 
not only substrates of DP4 but also key players in adaptive/stress responses. Their local N-
terminal truncation at the level of the hypothalamus (i.e. median eminence) might offer a novel 
and interesting avenue for the regulation of stress responsiveness.  
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Whereas NPY exerts a rather stress-modulatory role in the non-habituated hot plate task – 
resulting in a nociceptive response of DP4 deficient rats – i.c.v. NPY shows an antinociceptive 
effect, thus potentiating the analgesic action of NPY. NPY’s function within pain perception is 
controversially discussed but its presence in areas involved in pain modulation such as the 
periaqueductal gray, locus coeruleus, thalamus or in the dorsal horn of the spinal cord suggests 
an important role for NPY as a putative regulator of pain transmission and perception (Broqua 
et al., 1996). Although some studies describe pronociceptive (Lin et al., 2004; Ossipov et al., 
2002; Son et al., 2007; Tracey et al., 1995; White, 1997) or bilateral effects of NPY (Gibbs et 
al., 2007; Xu et al., 1999), the majority describes antinociceptive role of NPY (Hua et al., 
1991; Naveilhan et al., 2001; Taiwo and Taylor, 2002). For example, intranasal NPY 
application in humans significantly reduced capsaicin-evoked pain by 34% (Lacroix et al., 
1996). Using different animal models, NPY induces powerful antinociceptive effects in the 
acetic acid-induced writhing test and after thermal stimulation, which are probably mediated 
via the Y1 receptor (Broqua et al., 1996; Gibbs et al., 2007; Taiwo and Taylor, 2002; Wang et 
al., 2001; Xu et al., 1999). However, the analgetic-like effects of exogenously applied NPY 
seem to be dependent on the route of administration, the application dosage, and the intensity 
and modality of the painful stimulus (Broqua et al., 1996; Mellado et al., 1996). So, apart from 
species-specific effects, variations of these parameters have very likely led to divergent results 
for the role of NPY in pain  
In the current study, i.c.v. administration of NPY was found to have a more potent analgetic-
like effect on mutant F344 substrains than on control rats. Differential degradation of NPY, 
caused by DP4 deficiency, could lead to an increased Y1 receptor-like tone in mutant rats 
potentiating the dose-dependent analgesic/antinociceptive actions of NPY. The exclusive 
importance of the Y1 receptor for the antinociceptive-like potential of centrally applied NPY is 
described in genetic and pharmacological studies using Y1 receptor knockout mice (Naveilhan 
et al., 2001; Taiwo and Taylor, 2002). I.c.v. NPY had no further analgetic-like impact on 
control F344 rats as it is likely that these animals – caused by being tested in a non-habituated 
hot plate paradigm, which activates the rats’ stress response and therefore NPY release and 
stress-induced analgesia – exhibit a pain threshold at its maximum. 
Overall, these data provide further substantial evidence for the involvement of NPY-DP4-axis in 
stress-induced analgesia. 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 105 
 
4.5. Acknowledgements 
This work was supported by the DFG (GRK705 and Ka1837/1-1/2), by the Schizophrenia 
Research Institute (SRI) utilizing infrastructure funding from NSW Health; the Sylvia and 
Charles Viertel Charitable Foundation; a Bill Ritchie Postdoctoral Research Fellowship 
(awarded to TK) and the National Alliance for Research on Schizophrenia and Depression 
(Young Investigator Award awarded to TK). The critical comments by Liesl Duffy and Jerry 
Tanda on the manuscript are gratefully acknowledged. 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 106 
 
4.6. References 
Akil, H, Madden, J, Patrick, RL, Barchas, JD. Stress-induced increase in endogenous opiate 
peptides: Concurrent analgesia and its partial reversal by naloxone. In: Kosterlits, HW, editor. 
Opiates and Endogenous Opioid Peptides. Amsterdam: Elsevier, 1976, p 63-70. 
Amit, Z, Galina, ZH. Stress-induced analgesia: adaptive pain suppression. Physiol Rev 
1986;66:1091-1120. 
Bjelke, JR, Kanstrup, AB, Rasmussen, HB. Selectivity among dipeptidyl peptidases of the s9b 
family. Cell Mol Biol (Noisy-le-grand) 2006;52:3-7. 
Broqua, P, Wettstein, JG, Rocher, MN, Gauthier-Martin, B, Riviere, PJ, Junien, JL, Dahl, SG. 
Antinociceptive effects of neuropeptide Y and related peptides in mice. Brain Res 
1996;724:25-32. 
Chrousos, GP, Gold, PW. The concepts of stress and stress system disorders. Overview of 
physical and behavioral homeostasis. Jama 1992;267:1244-1252. 
Crofford, LJ, Pillemer, SR, Kalogeras, KT, Cash, JM, Michelson, D, Kling, MA, Sternberg, 
EM, Gold, PW, Chrousos, GP, Wilder, RL. Hypothalamic-pituitary-adrenal axis perturbations 
in patients with fibromyalgia. Arthritis Rheum 1994;37:1583-1592. 
De Meester, I, Durinx, C, Bal, G, Proost, P, Struyf, S, Goossens, F, Augustyns, K, Scharpe, S. 
Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 2000;477:67-87. 
De Meester, I, Korom, S, Van Damme, J, Scharpe, S. CD26, let it cut or cut it down. Immunol 
Today 1999;20:367-375. 
Gibbs, J, Flores, CM, Hargreaves, KM. Neuropeptide Y inhibits capsaicin-sensitive 
nociceptors via a Y1-receptor-mediated mechanism. Neuroscience 2004;125:703-709. 
Gibbs, JL, Diogenes, A, Hargreaves, KM. Neuropeptide Y modulates effects of bradykinin and 
prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors. Br J 
Pharmacol 2007;150:72-79. 
Gibbs, JL, Flores, CM, Hargreaves, KM. Attenuation of capsaicin-evoked mechanical 
allodynia by peripheral neuropeptide Y Y(1) receptors. Pain 2006. 
Guieu, R, Fenouillet, E, Devaux, C, Fajloun, Z, Carrega, L, Sabatier, JM, Sauze, N, Marguet, 
D. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain 
Res 2006;166:230-235. 
Heilig, M. The NPY system in stress, anxiety and depression. Neuropeptides 2004;38:213-224. 
Heilig, M, McLeod, S, Brot, M, Heinrichs, SC, Menzaghi, F, Koob, GF, Britton, KT. 
Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and 
dissociation from food intake effects. Neuropsychopharmacology 1993;8:357-363. 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 107 
 
Hildebrandt, M, Reutter, W, Arck, P, Rose, M, Klapp, BF. A guardian angel: the involvement 
of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. 
Clin Sci (Lond) 2000;99:93-104. 
Hua, XY, Boublik, JH, Spicer, MA, Rivier, JE, Brown, MR, Yaksh, TL. The antinociceptive 
effects of spinally administered neuropeptide Y in the rat: systematic studies on structure-
activity relationship. J Pharmacol Exp Ther 1991;258:243-248. 
Jolicoeur, FB, Michaud, JN, Rivest, R, Menard, D, Gaudin, D, Fournier, A, St-Pierre, S. 
Neurobehavioral profile of neuropeptide Y. Brain Res Bull 1991;26:265-268. 
Karl, T, Chwalisz, WT, Wedekind, D, Hedrich, HJ, Hoffmann, T, Jacobs, R, Pabst, R, von 
Horsten, S. Localization, transmission, spontaneous mutations, and variation of function of the 
Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats. Regul Pept 2003a;115:81-90. 
Karl, T, Hoffmann, T, Pabst, R, von Horsten, S. Behavioral effects of neuropeptide Y in F344 
rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 
2003b;75:869-879. 
Karl, T, Hoffmann, T, Pabst, R, Von Horsten, S. Extreme reduction of dipeptidyl-peptidase IV 
activity in F344 rat substrains results in major behavioral differences. Physiol Behav 
2003c;i80:123-134. 
Kask, A, Harro, J, von Horsten, S, Redrobe, JP, Dumont, Y, Quirion, R. The neurocircuitry 
and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav 
Rev 2002;26:259-283. 
Kask, A, Nguyen, HP, Pabst, R, Von Horsten, S. Neuropeptide Y Y1 receptor-mediated 
anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing 
hormone-induced anxiety. Neuroscience 2001;104:799-806. 
Kelley, DD. Stress-induced analgesia. Ann N Y Acad Sci 1986;467. 
Kelly, DD. The role of endorphins in stress-induced analgesia. Ann N Y Acad Sci 
1982;398:260-271. 
Lacroix, JS, Ricchetti, AP, Morel, D, Mossimann, B, Waeber, B, Grouzmann, E. Intranasal 
administration of neuropeptide Y in man: systemic absorption and functional effects. Br J 
Pharmacol 1996;118:2079-2084. 
Lin, Q, Zou, X, Ren, Y, Wang, J, Fang, L, Willis, WD. Involvement of peripheral neuropeptide 
Y receptors in sympathetic modulation of acute cutaneous flare induced by intradermal 
capsaicin. Neuroscience 2004;123:337-347. 
Madden, Jt, Akil, H, Patrick, RL, Barchas, JD. Stress-induced parallel changes in central 
opioid levels and pain responsiveness in the rat. Nature 1977;265:358-360. 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 108 
 
Mellado, ML, Gibert-Rahola, J, Chover, AJ, Mico, JA. Effect on nociception of 
intracerebroventricular administration of low doses of neuropeptide Y in mice. Life Sci 
1996;58:2409-2414. 
Mentlein, R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. 
Regul Pept 1999;85:9-24. 
Merlo Pich, E, Zoli, M, Zini, I, Ferraguti, F, Solfrini, V, Tiengo, M, Fuxe, K, Agnati, LF. 
Effects of central administration of neuropeptide Y on vigilance and pain threshold in 
spontaneously hypertensive rats. Adv Pain Res Ther 1990;13:55-62. 
Naveilhan, P, Hassani, H, Lucas, G, Blakeman, KH, Hao, JX, Xu, XJ, Wiesenfeld-Hallin, Z, 
Thoren, P, Ernfors, P. Reduced antinociception and plasma extravasation in mice lacking a 
neuropeptide Y receptor. Nature 2001;409:513-517. 
Obuchowicz, E, Krysiak, R, Herman, ZS. Does neuropeptide Y (NPY) mediate the effects of 
psychotropic drugs? Neurosci Biobehav Rev 2004;28:595-610. 
Ossipov, MH, Zhang, ET, Carvajal, C, Gardell, L, Quirion, R, Dumont, Y, Lai, J, Porreca, F. 
Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J 
Neurosci 2002;22:9858-9867. 
Rehbinder, C, Alenius, S, Bures, J, de las Heras, ML, Greko, C, Kroon, PS, Gutzwiller, A. 
FELASA recommendations for the health monitoring of experimental units of calves, sheep 
and goats. Report of the Federation of European Laboratory Animal Science Associations 
(FELASA) Working Group on Animal Health. Lab Anim 2000;34:329-350. 
Son, SJ, Lee, KM, Jeon, SM, Park, ES, Park, KM, Cho, HJ. Activation of transcription factor 
c-jun in dorsal root ganglia induces VIP and NPY upregulation and contributes to the 
pathogenesis of neuropathic pain. Exp Neurol 2007;204:467-472. 
Taiwo, OB, Taylor, BK. Antihyperalgesic effects of intrathecal neuropeptide Y during 
inflammation are mediated by Y1 receptors. Pain 2002;96:353-363. 
Thompson, NL, Hixson, DC, Callanan, H, Panzica, M, Flanagan, D, Faris, RA, Hong, WJ, 
Hartel-Schenk, S, Doyle, D. A Fischer rat substrain deficient in dipeptidyl peptidase IV 
activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell 
transplantation model. Biochem J 1991;273:497-502. 
Tiruppathi, C, Miyamoto, Y, Ganapathy, V, Leibach, FH. Genetic evidence for role of DPP IV 
in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 1993;265:G81-89. 
Tracey, DJ, Romm, MA, Yao, NN. Peripheral hyperalgesia in experimental neuropathy: 
exacerbation by neuropeptide Y. Brain Res 1995;669:245-254. 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 109 
 
von Horsten, S, Nave, H, Ballof, J, Helfritz, F, Meyer, D, Schmidt, RE, Stalp, M, Exton, NG, 
Exton, MS, Straub, RH, Radulovic, J, Pabst, R. Centrally applied NPY mimics 
immunoactivation induced by non-analgesic doses of met-enkephalin. Neuroreport 
1998;9:3881-3885. 
Wang, JZ, Lundeberg, T, Yu, LC. Anti-nociceptive effect of neuropeptide Y in periaqueductal 
grey in rats with inflammation. Brain Res 2001;893:264-267. 
Watanabe, Y, Kojima, T, Fujimoto, Y. Deficiency of membrane-bound dipeptidyl 
aminopeptidase IV in a certain rat strain. Experientia 1987;43:400-401. 
Wettstein, JG, Earley, B, Junien, JL. Central nervous system pharmacology of neuropeptide Y. 
Pharmacol Ther 1995;65:397-414. 
White, DM. Intrathecal neuropeptide Y exacerbates nerve injury-induced mechanical 
hyperalgesia. Brain Res 1997;750:141-146. 
Wolf, G, Yirmiya, R, Kreisel, T, Goshen, I, Weidenfeld, J, Poole, S, Shavit, Y. Interleukin-1 
signaling modulates stress-induced analgesia. Brain Behav Immun 2007;21:652-659. 
Xu, IS, Hao, JX, Xu, XJ, Hokfelt, T, Wiesenfeld-Hallin, Z. The effect of intrathecal selective 
agonists of Y1 and Y2 neuropeptide Y receptors on the flexor reflex in normal and axotomized 
rats. Brain Res 1999;833:251-257. 
 
 
Evidence for mediation via stress-protective effects of NPY: Pharmacol Biochem Behav, submitted 110 
 
4.7. Figures 
 
 
Fig. 1A (above) + B (below): DP4-like activity: DP4-like activity [mU/ml] of A) the newly 
generated congenic rat strain DA.F344-Dpp4m/SvH and of B) three different F344 rat 
substrains (F344/DuCrlSvH-Dpp4m, F344/Crl(Wiga)SvH-Dpp4m, F344/Crl(USA)) was 
analysed using blood taken from the tail vein. Data represent means ± SEM. Asterisks (***p < 
.001) reflect significant posthoc differences versus wild type-like rats of the A) DA/Ztm strain 
or B) F344/Crl(USA) substrain. 
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Fig. 2A (above) + B (below): Nociception: pain sensitivity was analysed in the non-habituated 
hot plate task - rats of the three different F344 substrains were tested after receiving an i.c.v. 
injection of vehicle or A) NPY (0.2 nmol/1 nmol) or B) Ile-Thia (0.5 nmol/5.0 nmol). The 
latency to respond (lick or raise a hindpaw) was recorded. Data represent means ± 
SEM.Asterisks (*p < .05; **p < .01) reflect significant posthoc differences versus 
F344/Crl(USA) rats. 
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Fig. 3: Nociception: pain sensitivity was analysed in the non-habituated hot plate task and 
again seven days later in the habituated hot plate task - rats of a wild type-like DA/Ztm and of 
a DP4 deficient congenic DA.F344-Dpp4m/SvH strain were tested. The latency to respond (lick 
or raise hindpaws) was recorded. Data represent means ± SEM. Asterisks (*p < .05; ***p < 
.001) reflect significant posthoc differences versus DA/Ztm rats. 
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Fig. 4A-F: Immunofluorescence photomicrographs of double labelled sections of rat 
hypothalamus immunostained for DP4-like immunoreactivity (ir) (artificial green, A, D) and 
NPYir (artificial red, B, E) as well as overlays (green, red, and blue DAPI stain; C, F). 
Representative cryosections derived from a DP4 positive F344 rat brain. Under a low 
magnification (x10), DP4ir material bordering the third ventricle and blood vessels could be 
detected. On the same bregma level, NPYir cell bodies could be detected within the PVN and 
the periventricular nucleus of the hypothalamus (B). Overlay of the photomicrographs (C) 
show a co-distribution of both proteins within the region of interest, which lack clear co-
expression. Under a higher magnification (x63), cells of the subependymal layer harbouring 
the third ventricle that show DP4ir cells are in direct contact with NPY neurophil. 
Abbreviations: 3V, third ventricle. Scale bar G, 100 mm; H, 10 mm. 
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5. Discussion 
The neuropeptide NPY is involved in various physiological processes. Due to its size of 36 aa 
and the N-terminal structure, NPY is one of the best in vivo substrates for DP4 and vice versa, 
DP4 is the best peptidase for N-terminal dipeptide truncation of NPY – demonstrated by 
catalytic turnover rates [97, 156, 157]. Since this interaction is of exceptional significance, but 
not fully understood, we studied the NPY-DP4-axis at three levels of potential regulatory 
importance: (1) cleavage of NPY by DP4/DP4-like peptidases, (2) in a congenic animal model 
of DP4 deficiency, and (3) within central processing of pain perception. 
Initially, we had to question which other peptidases are involved in the modulation of NPY 
receptor specificity. Another important aspect is the search for sources of N-terminally 
truncated NPY and related peptides (e.g. PYY). Thus, our first approach was the examination 
of DP4-NPY interactions on the molecular and cellular level combined with the potential 
cleavage of other DP4-like peptidases. Therefore, DP4 – isolated from wild type 
F344/Crl(USA) rats – and NPY were each cloned into fluorescence transport vectors. A simple 
transfection system was chosen to look for leadoff signs of possible shared transport processes 
in which intracellular cleavage of NPY by DP4 could occur. Internalization of DP4 is a 
reported mechanism in recycling of cell surface glycoproteins [158] or in association with T 
cell activation [159] that might offer the possibility of a co-localization with NPY and thus 
could potentiate intracellular truncation. Furthermore, co-localization of DP4 and NPY is 
suggested by Zukowska et al. who reported on a non-neuronal depot of NPY in endothelial 
cells [160]. So far, analysis of our model of co-transfected Cos-1 cells revealed that NPY and 
DP4 are not co-localized in transport vesicles. The process of co-localization could enable N-
terminal cleavage of NPY and thus precise and quick intracellular degradation of NPY1-36 to 
NPY3-36. This possibility could provide a tool for controlling activation of different NPY 
receptor subtypes and thus presents a fine-tuning mechanism in body functions. This idea is in 
contrast to the so far observed extracellular degradation of DP4 substrates which is based on 
circulating NPY and other substrates that get into contact with DP4. From this point of view, 
intracellular degradation seems to be a more efficient and economic way. 
Several peptidases named “structural and functional homologues of DP4” (DASH) represent 
potential candidates for cleavage of NPY, however with different levels of specificity and 
activity. Little was known about the degradation of natural substrates by these DASH and their 
physiological role at the time when phenotyping and characterization of the previously used 
animal model of F344 rats started [146]. While former research distinguished between DP4 
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and DP2 activity and thus, mainly focused on DP4, the use of DASH specific inhibitors just 
became a standard in preclinical research [161-163]. So for example, Lankas et al. reported on 
studies with broad-specificity DASH inhibitors and highly selective inhibitors of DP4, DP2, 
and DP8/9 for the assessment of preclinical safety and tolerability in a study in 2005 [164]. 
To examine the potential involvement of different peptidases in NPY cleavage, selective 
inhibitors were applied against DP4, DP8/9 and DP2, and enzymatic distribution and activity 
studies associated with MALDI-TOF analyses were conducted. Using the chromogenic 
substrate Ala-Pro-AMC and selective inhibitors, examination of peptidase activity of brain 
extracts from wild type and DP4 deficient F344 rat substrains revealed highest distribution for 
DP2 followed by DP8/DP9 and finally DP4. However, DP2 was unable to hydrolyze human 
recombinant NPY and thus could be excluded. Although DP8/DP9 are presented in higher 
levels in the brain than DP4, MALDI-TOF-mass spectrometry showed similar cleavage of 
NPY by DP4 and DP8/DP9, confirming the higher catalytic efficiency of DP4 [156]. In 
contrast, analysis of human plasma showed highest degradation of NPY by DP4 and partial 
degradation by DP8/DP9. In addition, we report on the potency of APP from brain extracts on 
N-terminal cleavage of NPY resulting in NPY2-36 (detected via MALDI-TOF). 
Preliminary results obtained by histochemistry on DASH specific enzymatic reactions suggest 
a dominant presence of DP4 at the meninges, CVOs and vessels and a dominant ubiquitously 
distribution of DP8/DP9 in the brain. Taken together, these findings support the idea that 
peripheral NPY is preliminarily truncated by soluble serum DP4, endothelial DP4 (blood 
vessels), or when crossing the blood-brain barrier by membrane-bound DP4 at the meninges, 
whereas NPY released from neurons in the brain also seems to be degraded to a large extent by 
DP8/DP9. Neither the histology nor the cytology of NPY cleavage are sufficiently understood 
at this time and demand further in-depth studies. Interestingly, there is no compensation of the 
loss of DP4 activity in DP4 deficient F344 rats by DP8 or DP9, which is in correspondence 
with the below mentioned differential NPY levels, which might influence behavioural 
responses. 
 
In a second step we generated a novel DP4 deficient congenic animal model on a defined DA 
rat genetic background with pronounced differences in DP4 activity between congenic and 
wild type strains and studied the effects of this genetically induced DP4 deficiency in a 
comprehensive phenotyping approach. For generation of congenic DA.F344-Dpp4
m
/SvH rats, 
the previously characterized spontaneous point mutation in the Dpp4 gene of the F344 rat 
substrains F344/DuCrjSvH-Dpp4
m
 and F344/Crl(Wiga)SvH-Dpp4
m
 was transferred onto the 
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genetic background of DA/Ztm rats. These DP4 deficient animals are comparable to gene 
knockouts and provide a basis for learning more about the consequences of chronic DP4 
deficiency, which is presently introduced into clinics as a treatment of diabetes type 2 via 
chronic pharmacological inhibition of DP4 [162, 165]. Whereas the previous model of DP4 
deficient F344 rats mainly focused on behavioural tests to elucidate the role of DP4, our 
comprehensive phenotyping also comprised – next to neurobehavioural parameters – 
endocrine, hematological, metabolic, and immune parameters for better evaluation of effects 
that might be affected by DP4 deficiency.  
First we studied parameters related to glucose metabolisms and body weight homeostasis in the 
DA.F344-Dpp4m/SvH rats. Thus, we found that glucose tolerance seems to be inversely related 
to DP4-like activity levels because heterogenous animals – according to the characteristic 
semi-dominant mode of inheritance, expressing half of the DP4-like activity – show a rather 
intermediate development of glucose lowering in blood. The improved glucose tolerance in 
DA.F344-Dpp4m/SvH rats is associated with increased levels of GLP-1 and higher amounts of 
circulating insulin which were additionally detected. GLP-1 is a substrate of DP4 that 
stimulates insulin gene expression, increases glucose-stimulated insulin secretion [166, 167], 
and inhibits glucagon secretion – all of which contribute to normalize elevated blood glucose 
levels [168]. DP4 deficiency leads due to missing protease activity to a prolonged half-life of 
GLP-1. Similar effects are achieved by use of DP4 inhibitors [166, 169, 170]. For example, the 
DP4 inhibitor Ile-Thia (isoleucine thiazolidide; P32/98) is reported to decrease circulating DP4 
activity and to improve glucose tolerance in Zucker fatty rats [170], and the DP4 inhibitor 
NVP-Dpp728 is said to increase levels of intact GLP-1, to improve glucose tolerance, and to 
increase glucose-stimulated insulin secretion [171]. 
Although glucagon-like peptide-1(7-36)amide (GLP-1) and also the DP4 substrate glucose-
dependent insulinotropic polypeptide (GIP) are involved in the regulation of postprandial 
nutrient homeostasis [172], no significant effects of these peptides on food intake are assumed 
in our congenic animal model. Interestingly, reduced body weight gain on standard but also on 
high fat diet was observed in DP4 deficient rats while food-intake was not significantly altered. 
These findings of reduced body weight gain combined with non-altered food intake are 
supported by data from Zucker fatty rats, where long-term treatment with Ile-Thia (P32/98) 
decreased body weight gain without affecting food intake [173]. Conarello et al. observed a 
significantly increased weight gain in wild type (C57BL/6) mice with restricted high calorie 
diet food intake in comparison to Dpp4tm1Nwa mice, also suggesting that other factors than food 
intake contributed to reduced weight gain and to resistance in obesity [174]. Even though NPY 
Discussion  117 
 
is known to stimulate the feeding behaviour [175-180] and to act as appetite transducer [108], 
food-intake was obviously not affected by endogenous NPY levels. In agreement with this, 
mice deficient for NPY were reported to have normal food intake and body weight, and 
become hyperphagic following food deprivation [154]. 
Interestingly, Hildebrandt et al. [181] suggest that there exists an interaction between DP4 and 
leptin, i.e. leptin deficiency. Leptin is reported to affect energy expenditure in rodens and 
humans [182, 183]. Activation of central leptin receptors (ObRbs) stimulates energy 
expenditure in adipose tissue [184]. Furthermore, the arcuate nucleus in the hypothalamus 
[113], a high expression site of ObRbs [185, 186], is a major site of leptin sensing [187-190]. 
Peripheral leptin is transported across the blood-brain barrier to reach areas distal to CVOs 
[191]. In this context it is of interest that the ARH contains at least two key populations of 
leptin-responsive neurons – one of them expresses the orexigenic peptide NPY and agouti-
related peptide (AgRP) [192]. However, it has been shown that NPY deficient mice decrease 
their food intake and lose weight, initially to a greater extent than controls, when treated with 
recombinant leptin [154]. This leads to the suggestion that more complex systems are involved 
in body weight regulation than simple degradation of DP4 substrates that enhance or reduce 
stimulation of appetite. Moreover, differential effects resulting from various protein and 
peptides could possibly abrogate each other. So, the above mentioned findings suggest an 
interaction between DP4 and leptin and thus, it is very likely that increased levels of bound 
leptin and reduced levels of free leptin – that were observed in DA.F344-Dpp4m/SvH rats – are 
cohesive with a reduction in body weight and are associated with DP4 activity or deficiency, 
respectively.  
Additionally, reduced levels of triglycerides – also reported from studies of Ahren et al. [193] 
– and alanine aminotransferases as well as aspartate aminotransferases were observed, 
supporting the idea of an improved lipid metabolism. However, these coherences have to be 
studied in more detail. So far, the phenotype of DP4 deficient DA rats goes along with various 
levels of “beneficial” effects amongst others improved glucose tolerance and reduced body 
weight and obviously protects from high-fat diet induced obesity. The latter could also be 
observed in Dpp4tm1Nwa mice, which are proposed to resist hepatic lipid accumulation when fed 
a high-fat diet [174]. Additionally, these mice are reported to show increased energy 
expenditure, which fits well with the abovementioned influence of leptin on energy 
expenditure. 
Importantly, the influence of DP4 activity on digestion of gliadin-rich food could be 
demonstrated in our DA rats and is reflected by weight loss. Gliadin is a proline-rich 
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compound of gluten and causes, as a well-known allergen, the histamin reaction in celiac 
disease. DP4 is highly expressed in the ileum and jejunum. Since the role of DP4 in the small 
intestine is dipeptide re-absorption after cleavage of proline containing peptides and 
oligopeptides [149, 194], DP4 deficiency leads to an impaired intestinal absorption of certain 
proline-rich peptides [149] such as gliadin, as observed in F344 rats by Tiruppathi [194]. The 
small intestine has effective carrier transport systems for amino acids, di- and tripeptides, while 
peptides with longer chain length, e.g. tetrapeptides, require hydrolysis prior to absorption. In 
this context it was shown, that prolyl tetrapeptides such as Leu-Pro-Gly-Gly and Gly-Pro-Gly-
Gly require hydrolysis by DP4 [195]. In addition, it has to be noted that DP4 is highly 
expressed in kidney and there – similar to the intestine – is involved in dipeptide re-absorption 
[196-199]. Thus, studies in DP4 deficient F344 rats have shown that DP4 deficient rats were 
unable to hydrolize and absorb urinary prolyl peptides, which are excreted in high amounts by 
these animals [199]. 
Furthermore, we suggest a connoting relevance of DP4 in regard to the processing of the 
casein-derived -casomorphin that can be affected by application of DP4 inhibitors. In 
comparison to human -casomorphin-7 (BCM-7; NH2-Tyr-Pro-Phe-Val-Glu-Pro-Ile-CO2H), 
bovine BCM-7 (NH2-Tyr-Pro-Phe-Pro-Gly-Pro-Ile-CO2H) reveals an additional cleavage site 
for DP4. While the function of human BCM is rather restricted to the lactation period, bovine 
BCM-7 displays high relevance in human nutrition when consuming milk products. Although 
human BMC-7 shows high immune reactive (allergy-inducing) potency, the bovine BMC-7 
and its derivates are reported to be much more reactive. Thus for example, regardless of the 
comparative physiological function between human and bovine derived casomorphins, human 
beta-casomorphin-5 (Tyr-Pro-Phe-Val-Glu) is about ten times less potent than bovine beta-
casomorphin-5 (Tyr-Pro-Phe-Pro-Gly) [200]. To demonstrate the power of casomorphin, it can 
be noted that in that study approximately ten times more naloxone was required in rats to 
antagonize the beta-casomorphin-5 effect than that of morphine. Importantly, a potential 
connexion of bovine BMC-7 with schizophrenia is discussed. Since exorphins like 
casomorphin may be implicated in disorders such as autism and schizophrenia, attention should 
be paid to this aspect when targeting DP4 in vivo. Additionally, an association between casein-
rich and casein-free nurishment and regulation of opiate receptor expression was observed in 
postnatal rats [201]. 
In this context, websites can be found in the Internet, selling or giving information on DP4-
containing pharmaceuticals as alternative for a gluten-free, casein-free (GFCF) diet. These 
approaches are in contrast to the idea of a DP4 inhibitor and thus on the one hand, question the 
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effects of inhibitors on digestion but on the other hand, the so far observed effects – resulting 
from DP4 deficiency and inhibition – question these DP4-containing pharmaceuticals. This 
strongly requires to consider all consequences and functions of DP4 activity and inhibition and 
not to observe single aspects in a closed regulatory loop. The comprehensive phenotyping of 
novel animal models of DP4 deficiency represents an important approach to fulfill these 
rationals. 
Thus, a comprehensive phenotyping is absolutely necessary for the appraisal of the influence 
of DP4 on neurobehavioural aspects in DP4 deficient DA.F344-Dpp4m/SvH rats. Our analyses 
focused on behavioural domains related to anxiety, stress responsiveness, exploration, 
motorfunction, and cognition.  
Testing of cognition or of schizophrenic-like responses (PPI) revealed no significant 
differences in our DP4 deficient model. Thus, the two-way active avoidance test reflected that 
both DA rat strains – DP4 deficient as well as wild type DA/Ztm rats – were able to learn and 
that none of the substrains differed significantly. This is also supported by findings in one-
year-old transgenic NPY-overexpressing rats that showed no significant differences in spatial 
and non-spatial memory (Morris water maze and object recognition test) [150]. The PPI test 
showed that all animals clearly responded to the startle signaling in a similar manner – 
indicating healthy and equal hearing abilities. From this point of view and in addition to basic 
health control, we were able to state that no rat strain was advantaged or disadvantaged in the 
conduction of behavioural tests. 
No significant differences in motorfunctions and behavioural activity were observed between 
wild type and DP4 deficient DA rats in the accelerod test, the holeboard test, and in the 
homecage activity test. Non-altered levels of activity and motorfunctions are important for the 
evaluation of further behavioural assays and have also been reported from NPY-overexpressing 
transgenic rats in another locomotor test [151]. Thus, the observed behavioural differences are 
not affected by altered levels of activity and motorfunctions. Furthermore, it can be excluded 
that differential activity levels have led to the reduced gain in body weight in DA.F344-
Dpp4m/SvH rats.  
DP4 deficient DA.F344-Dpp4m/SvH rats revealed significantly increased exploratory 
behaviour in the holeboard tests and significantly reduced anxiety-like behaviour in the 
classical and pharmacological validated EPM and SI test. In support of this, transgenic NPY-
overexpressing rats were shown to be resistant to acute physical restraint stress – measured by 
the EPM – and showed anxiolytic-like activity in an open field test [150]. Stress-induced 
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hyperthermia revealed significantly reduced body temperature values in DP4 deficient rats, 
indicating that the appraisal of a novel environment is percepted less stressful in a status of 
DP4 deficiency. Moreover, reduced levels of ACTH and corticosterone were detected in blood 
plasma. This indicates that the hypothalamic-pituitary-axis as well as the sympathetic response 
to stress are blunted in a status of DP4 deficiency. 
This finding of a reduced stress response in DP4 deficient rats probably also relates to the 
central processing of pain perception in our third approach concerning the NPY-DP4-axis. In 
this study, the nociceptive response in the DP4 deficient rat substrains F344/DuCrjSvH-Dpp4m, 
F344/Crl(Wiga)SvH-Dpp4m, and DA.F344-Dpp4m/SvH was determined using the hot plate test 
for different approaches. 
In comparison to wild type DA/Ztm rats DP4 deficient DA rats showed a significant earlier 
response towards the painful stimulus in the non-habituated hot plate test. Thus, previous 
findings from DP4 deficient F344 substrains [147] could be replicated – even with an earlier 
reaction in DA rats in comparison to F344 rats that might be influenced by two-fold higher 
endogenous DP4 activity levels. Significant response differences of the non-habituated hot 
plate tests were reversed after habituation – obviously resulting from a pronounced reduction 
in stress in wild type controls. These findings suggest a mechanism of reduced stress-induced 
analgesia in DP4 deficient rats, which might be caused by reduced release of endogenous 
opioids or other mediators due to the lowered stress-response at baseline conditions. 
This phenomenon of stress-induced analgesia appears to present an adaptational response of 
the organism to stress, which also could be demonstrated in early experiments of acute stress 
preceeding the test of hot plate paradigm [202-204]. Here, stress-induced analgesia was 
reversed by habituation. Furthermore, stress-induced analgesia was accompanied by an 
increase in brain endogenous opioids [203]. This phenomenon can be antagonized by non-
specific centrally acting opiod antagonists such as naloxone for example [202]. A further 
aspect is that pain, and any kind of stress – whether psychological, infectious or traumatic – 
activates corticotropin-releasing hormone (CRH) neurons [205, 206]. Stress-induced activation 
of the hypothalamic-pituitary axis has been shown to produce analgesia [207] and it was 
demonstrated that CRH can act at all levels of the neuronal axis to produce analgesia 
independent of the release of -endorphin [208].  
Furthermore, i.c.v. application of either NPY or the DP4 inhibitor Ile-Thia (P32/89), previously 
conducted in DP4 deficient F344 substrains, revealed an antinociceptive effect of NPY on the 
one hand, and a reduced treshold in pain perception caused by the DP4 inhibitor on the other 
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hand. While the latter approach supported the abovementioned observations of the genetic 
model (reduction in stress-induced analgesia), the role of NPY in pain perception and 
processing is controversially discussed. A survey of the literature on NPY in pain [209] has 
revealed that 52% of these studies describe an antinociceptive role [210-213], around 29% a 
pronociceptive action [214-219] and 19% reported on bilateral effects [220, 221]. A reason for 
divergent results might be derived from the experimental setting (e.g. study objects, way of 
application/local effect, pain stimulus), which again influences the activation of different 
receptors. 
NPY is assumed to exert antinociceptive actions amongst others by inhibiting the release of SP 
and other “pain neurotransmitters” in the spinal cord dorsal horn. Studies in Y1 receptor KO 
mice suggest the involvement of the Y1 receptor in central physiological and pharmacological 
NPY-induced analgesia [212]. In agreement with this, Gibbs et al. suggest that the 
antinociceptive effects of NPY are likely due to activation of the Y1 receptor, and could be 
mediated – at least in part – by inhibition of exocytosis of neuropeptides from the spinal cord 
[210, 222]. In addition, pain transmission through nociceptive sensory neurons expressing 
several types of NPY receptors might be modulated in different ways [209]. For example, 
seven distinct Y1 receptor neuron populations have been identified in the rat lumbar spinal cord 
– all being located at different lamina layers [223]. Next to the Y1 receptor, the Y2 receptor is 
also taken into account in the role of pain transmission [209] dependent on local site of 
activation.  
As nociceptive information is modulated on every level of the CNS via different receptor 
systems and mediators, this study is a first step in understanding the complex network of pain 
perception and processing and its endogenous modulation in response to challenge. However, 
this phenomenon clearly illustrates the stress-protective effects of DP4 deficiency.  
Our novel animal model impressively exhibits a stress protective and anxiolytic-like phenotype 
that – following our hypothesis – is substantially caused by the prolonged half-life of 
endogenous NPY1-36 which binds with high affinity the NPY Y1 receptor. This receptor is 
mainly responsible for NPY mediated anxiolysis and stress-protection [112, 151]. In wild type 
DA/Ztm rats N-terminal cleavage of NPY by DP4 leads to NPY3-36, which again has a much 
lower Y1 receptor affinity, thereby abrogating anxiolytic-like action of NPY and thus 
explaining the observed behavioural differences between DA/Ztm and DA.F344-Dpp4m/SvH 
rats. We assume that these stress-reduced and anxiolytic-like responses are mediated via the 
interaction between DP4 and NPY at the level of the hypothalamus, where high expression of 
NPY and DP4 in blood vessels is apparent (Frerker et al., 2007 submitted). 
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Examination of the immunological status of DP4 deficient DA rats revealed a differential 
leukocyte subset composition, blunted immune cell functions and altered Il-6 levels. 
Accordingly, this first immunological approach questions – next to the abovementioned 
considerable impaired absorption and degradation processes – the so far declared “healthy 
phenotype” of our DP4 deficient animal models of F344 and congenic DA rats as well as of 
DP4 knockout in general. 
The differential distribution of eosinophils and B cells might result from indirect effects of 
DP4 via cleavage of chemokines that might either affect hematopoetic stem cells or cell and 
progenitor cell mobilization. Concerning blunted T cell proliferation, this is very likely due to 
the direct role of DP4 as surface marker in T cell activation and co-stimulation as it could be 
shown that DP4 interacts with caveolin-1 and thus mediates the co-stimulatory and 
proliferation cascade [77, 78]. Thus, T cell functions might be affected at very different 
regulatory levels including but not limited to antigen presenting cell/T cell interaction, T cell 
co-stimulation, and memory function [77]. Furthermore, the switch of T memory cells to 
regulatory T cells [224] might be affected and, importantly, also the chemokine metabolism 
[225, 226]. With respect to the latter, affected chemokines themselves act again on the immune 
cells. Thus, chemokines such as RANTES have been shown to act as regulators of T cell 
differentiation [227] and have been associated with a T helper cell 1 response [228], which 
strongly underlines the importance of DP4 in chemokine cleavage and stresses the potential  
resulting effects of DP4 deficiency/inhibition on the immune system. 
In this context, it could be shown that inhibition of enzymatic DP4 activity leads to increased 
release of the immuno-suppressive cytokine TGF-ß1 from T cells, which in turn leads to a 
suppression of the proliferation of these cells and to an inhibition of the production of immune-
stimmulating cytokines (IL-2, IL-12, IFN-) [229, 230].  
As previously reported from F344 rats [146], we confirmed blunted NK cell mediated 
cytotoxicity against tumor cell targets. However, in addition we also supply percentage and 
numbers, respectively, from splenic and peripheral blood NK cells and thus were able to 
specify this observation. Due to the higher number of NK cells in DP4 deficient DA.F344-
Dpp4m/SvH rats the over-all cytotoxicity (per rat) was not significantly altered in comparison 
to wild type DA/Ztm rats but taken the single NK cell, cytotoxicity is significantly reduced. 
Previous works showed that specific DP4 inhibitors had no effect on NK cell 
function/cytotoxicity but instead suppressed DNA synthesis and cell cycle progression of NK 
cells [42, 231] cells. They interpreted these findings with DP4 being involved in the regulation 
of NK cell proliferation whereas they suggested an independent regulation for natural 
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cytotoxicity. This is in contrast to our findings of increased NK cell levels in DP4 deficient 
rats, thus, disproving a suppression of DNA synthesis, and in addition, cytotoxic abilities per 
NK cell were affected – namely reduced. Probably these differential findings are derived from 
different experimental approaches or even might result as artefact from the DP4 inhibitors 
used. Nonetheless, our data suggest a role of DP4 in NK cell mediated tumor lysis and in NK 
cell distribution. 
 
In summary, the key findings of this DP4 deficient congenic model are improved glucose 
tolerance, reduced body weight, improved leptin and liver metabolism, and an anxiolytic and 
stress-reduced phenotype, all of them presenting actual or potential fields of pharmaceutical 
application (e.g. diabetes, obesity, psychiatric disorders). However, further key aspects are 
mal-utilization of proline-rich proteins (intestine, kidney) and importantly, immune alterations. 
By virtue of the restriction in a rats’ or mice’s life-span our observations are limited but might 
have severe effects in aging humans. In addition, effects of DP4 deficiency/inhibition might be 
clearly pronounced at infectious states. Due to the pleiotropic role of DP4, our animal model is 
pointing out that on the long run chronic DP4 inhibitors have the potential to interfere with 
CNS, immune, and physiological functions in vivo. Thus, we advise against side effects of the 
newly introduced anti-diabetic pharmaceuticals that might occur, if not tested appropriately. 
Furthermore, more specific inhibitors should be taken into account, for example DP4-resistant 
agonists on GLP-1 basis. A number of different GLP-1 analogues – so called “incretin 
mimetics” – with more favorable pharmacokinetic profiles have been generated and are 
currently studied in clinical trials. 
Last but not least it has to be mentioned that specificity of DP4 inhibitors must not only be 
restricted to the target action but also to the inhibitor itself. This means that applied DP4 
inhibitors have to be highly specific for DP4 and any kind of interference with the 
abovementioned functional homologues of DP4 or further peptidases has to be avoided. To 
give an example, a number of DP4 and DP4-like inhibitors have recently been tested for 
selectivity to DP4, DP8, DP9, and DP2 and their potential toxicity and tolerability was 
evaluated. The DP8/9-selective inhibitor produced thrombocytopenia, reticulocytopenia, 
alopecia, multiorgan histopathological changes, enlarged spleen, and mortality in rats. In dogs, 
this inhibitor produced gastrointestinal toxicity. Furthermore, the DP2-selective inhibitor 
produced reticulocytopenia in rats. Toxic effects of isomeric forms of the DP4 inhibitor Ile-
Thia were observed at very high doses of administration and include thrombocytopenia, ataxia, 
seizures, convulsions, tremor, diarrhoea, and adverse effects on the lungs after four weeks’ 
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treatment [164]. These findings were explained by off-target inhibition, which all in all again 
underlines the importance of highly selective inhibitors against DP4 itself. 
Overall, these studies unequivocally demonstrate that DP4 represents indeed a multifunctional 
enzyme and remains the main dipeptidyl peptidase in modulation of the neuropeptide’s 
receptor specificity. DP4 deficiency was shown to affect several adaptational responses many 
of them being under control of NPY.  
As the “beneficial phenotype” of DP4 deficient rats is accompanied by considerable changes in 
immune functions, these findings are of particular interest for the further design and use of 
DP4-specific inhibitors that are presently available for treatment of diabetes type II and which 
– in the future – may also target immune and CNS functions.  
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